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Abstract
The decision of endocrine breast cancer treatment relies on ERα IHC-based 
assessment. However, ER positivity does not predict response in all cases in 
part due to IHC methodological limitations. We investigated whether ESR1 
and ESR2 gene expression and respective promoter methylation may be 
related to non-favorable outcome of a proportion of tamoxifen treated patients 
as well as to ERα and ERß loss. Formalin-fixed paraffin-embedded breast 
cancer samples from 211 patients diagnosed between 1988 and 2004 
were submitted to IHC-based ERα and ERß protein determination. ESR1 
whole mRNA and promoter C specific transcript levels, as well as ESR2_ß1, 
ESR2_ß2/cx, and ESR2_ß5 transcripts  were assessed by real-time PCR. 
ESR1 promoters A and C, and ESR2 promoters 0N and 0K were investigated 
by CpG methylation analysis using bisulfite-PCR for restriction analysis, or 
methylation specific PCR. Due to the promising results  related to ESR1 
promoter methylation, we have used a quantification method by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS) together with Epityper software to measure methylation at 
promoters A and C. mRNA stability was assessed in actinomycin D treated 
MCF-7 and MDA-MB-231 cells. ERα protein was quantified using transiently 
transfected breast cancer cells. Low ESR1_C transcript levels were 
associated with better overall survival (p = 0.017). High levels of ESR1_C 
transcript were associated with non-favorable response in tamoxifen treated 
patients (HR = 2.48; CI 95% 1.24-4.99), an effect that was more pronounced 
in patients with ERα/PgR double-positive tumors (HR = 3.41; CI 95% 
1.45-8.04). The ESR1_C isoform had a prolonged mRNA half-life and a more 
relaxed 5’UTR structure compared to ESR1_A isoform. Western-blot analysis 
showed that at protein level, the promoter selectivity is  undistinguishable. 
There was no correlation between levels of ESR2 isoforms or ESR2 promoter 
methylation and ERß protein staining. ESR1 promoter C CpG methylation and 
not promoter A was responsible for ERα loss. We propose ESR1_C levels as 
a putative novel marker for breast cancer prognosis and prediction of 
tamoxifen response.
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Resumo
A decisão da terapêutica hormonal no tratamento do cancro da mama baseia-
se na determinação do receptor de estrogénio alfa por imunohistoquímica 
(IHC). Contudo, a presença deste receptor não prediz a resposta em todas as 
situações, em parte devido a limitações do método IHC. Investigámos se a 
expressão dos genes ESR1 e ESR2, bem como a metilação dos respectivos 
promotores, pode estar relacionada com a evolução desfavorável de uma 
proporção de doentes tratados com tamoxifeno assim como com a perda dos 
receptores de estrogénio alfa (ERα) e beta (ERß). Amostras de 211 doentes 
com cancro da mama diagnosticado entre 1988 e 2004, fixadas  em formalina 
e preservadas em parafina, foram utilizadas  para a determinação por IHC da 
presença dos receptores ERα e ERß. O mRNA total do gene ESR1 e os 
níveis específicos do transcrito derivado do promotor C (ESR1_C), bem como 
dos transcritos ESR2_ß1, ESR2_ß2/cx, and ESR2_ß5 foram avaliados por 
Real-time PCR. Os  promotores A e C do gene ESR1 e os promotores 0K e 
0N do gene ESR2 foram investigados por análise de metilação dos 
dinucleotidos CpG usando bisulfite-PCR para análise com enzimas de 
restrição, ou para methylation specific PCR. Atendendo aos resultados 
promissores relacionados com a metilação do promotor do gene ESR1, 
complementamos o estudo com um método quantitativo por matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
suportado pelo software Epityper para a medição da metilação nos 
promotores A e C. Fez-se a avaliação da estabilidade do mRNA nas linhas 
celulares de cancro da mama MCF-7 e MDA-MB-231 tratadas com 
actinomicina D. Baixos níveis do transcrito ESR1_C associaram-se a uma 
melhor sobrevivência global (p = 0.017). Níveis  elevados do transcrito 
ESR1_C associaram-se a uma resposta inferior ao tamoxifeno (HR = 2.48; CI 
95% 1.24-4.99), um efeito mais pronunciado em doentes  com tumores de 
fenótipo ERα/PgR duplamente positivo (HR = 3.41; CI 95% 1.45-8.04). A 
isoforma ESR1_C mostrou ter uma semi-vida prolongada, bem como uma 
estrutura secundária da região 5’UTR muito mais relaxada em comparação 
com a isoforma ESR1_A. A análise por Western-blot mostrou que ao nível da 
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proteína, a selectividade de promotores é indistinguivel. Não se detectou 
qualquer correlação entre os níveis das isoformas do gene ESR2 ou entre a 
metilação dos promotores  do gene ESR2, e a detecção da proteína ERß. A 
metilação do promotor C do gene ESR1, e não do promotor A, foi 
responsável pela perda do receptor ERα. Estes resultados sugerem que os 
níveis do transcrito ESR1_C sejam usados como um novo potencial 
marcador para o prognóstico e predição de resposta ao tratamento com 
tamoxifeno em doentes com cancro da mama.
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Chapter 1. Introduction
1.1. Epidemiology of breast cancer
At the outset of the 21st century, breast cancer remains one of the most 
prevalent cancers, the leading cause of cancer death among women 
worldwide1. Incidence rates have risen approximately 30% over the past 25 
years in western countries. The same tendency has been seen in developing 
countries. Although the reasons are not completely understood, changes in 
reproductive patterns, increased screening and decrease on physical activity 
are thought to be involved. The most recent report of the American Cancer 
Society estimates for US, during 2008, are 182,460 new cases of invasive 
breast cancer and 67,770 new cases  of carcinoma in situ2. According to this 
source, in the period of 2001-2004, there was a decrease in the incidence of 
breast cancer in the US due to reduction of hormone replacement therapy, as 
well as from mammography screening. Differently from other cancers  where 
the socioeconomic context directly influences the onset of distinct types of 
cancer, breast cancer incidence follows a similar tendency in developed and 
developing countries.  
1.2. Estrogens 
1.2.1. Synthesis, transport and metabolism 
The investigation of factors affecting the development of breast cancer has 
shown that steroid hormones have a central role in directing the growth of 
these tumors. Among naturally occurring C18 steroid hormones 
androstenedione and testosterone derived from cholesterol are the obligatory 
precursors of estrogens. In three consecutive hydroxylating reactions the 
P450 aromatase monooxygenase enzyme complex catalyzes their conversion 
into estrone and estradiol, respectively. This aromatization reaction is  the last 
step in the estrogen formation (Figure 1). In the liver, estradiol can be 
converted into estriol. In pre-menopausal women, estradiol originates from the 
theca and granulosa cells of the ovaries that produce both androgens  and 
estrogens. In men, aromatase activity is  located in Leydig cells of the testis. 
Aromatization also takes place in muscle, fat and nervous tissue in both 
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sexes3. In post-menopausal women estrone is the predominant estrogen 
synthesized through extra-gonadal testosterone conversion as  a function of 
age and body weight. In fact, in peripheral tissues, estrogens  production and 
inter-conversion depend on the local expression and activity of the aromatase, 
while during the reproductive period gonadotropines control estrogen 
production. Estrogens are metabolized by hydroxylation and subsequent 
methylation forming catechol and methoxylated estrogens, namely 2-
hydroxyestrogens, 4-hydroxyestrogens, and 16α-hydroxyestrogens. Among 
the various phase 1 metabolites, 4-hydroxyestrone and 16α-hydroxyestradiol 
are considered to be carcinogenic4. Elimination takes place by sulfation and 
glucuronidation, and the conjugates are excreted into the bile or urine.  
Fig. 1 Pathways of estrogen biosynthesis. DHEA, Dihydroepiandrosterone; E1, Estrone; E2, 
17ß-Estradiol; HSD, Hydroxysteroid dehydrogenase; CYP, Cytochrome P450 enzymes; scc, 
steroid cholesterol side chain scission; arom, aromatase; KSR, ketosteroid redutase. From 
the obligatory estrogen precursors androstenedione is the main form in ovaries and 
testosterone in extra-gonodal tissues.  
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1.2.2. Molecular mechanisms and actions
The specific nuclear actions of estrogens are determined by the subtype, or 
by isoforms of the ER involved, the structure of the hormone, the 
characteristics  of the target gene promoter, and the balance of co-activators 
and co-repressors that modulate the final transcriptional response to 
complexes of estrogen and ER3.  
The classical pathway 
Ligand dependent receptor activation
The ER is a transcription factor that once activated establishes nuclear inter-
action by binding to regulatory regions  of estrogen target genes. Free 
estrogen diffuses into the cell and binds to the Ligand Binding Domain (LBD) 
of the ER protein. ER is  a predominantly nuclear protein existing in an inactive 
complex with receptor-associated proteins such as heat-shock protein 90. 
These proteins serve as chaperones that stabilize the un-activated receptor 
and quench the DNA Binding Domain (DBD).  Upon ligand binding, the 
receptor dissociates from its cytoplasmatic chaperons and the estrogen-ER 
complex translocates into the cell nucleus. Hormone binding induces 
conformational changes that activate the receptor5, allow it to dimerize, and to 
bind to specific consensus sites in promoters  of target genes (Figure 2a). For 
ER, these elements are evolutionary conserved palindromic sequences 
separated by three variant bases (5’-GGTCAnnnTGACC-3’), also known as 
estrogen responsive elements (ERE). Activated ligand-receptor complex 
recruits co-activators to induce transcription of target downstream genes. 
Variants of ERE, differing in one or more bases, or even being partial ERE 
separated by many base pairs have been described. The former type of 
variant affects  affinity to ER6 and the latter can confer estrogen 
responsiveness when partial elements  act in combination7. When estrogen 
target genes lack functional ERE, estrogen may act by modulating the activity 
of other transcription factors such as the activating protein 1 (AP-1). In this 
case the binding of ER to the sub-units of AP-1, Jun and Fos, generates the 
formation of a transcription factor8. 
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           Fig. 2 Mechanisms of ER action. The classical pathway is represented by nuclear 
           models and the alternative pathway by plasma membrane/nuclear models.
Alternative pathways 
Ligand independent activation of ER
In the absence of hormonal ligand, the ER function can be altered by means 
of phosphorylation at specific serine or tyrosine residues. Mitogen-activated 
protein kinases  (MAPK) and receptor tyrosine kinases (TK) mediate this 
reaction upon activation by growth factors signals. Activated MAPK elicit the 
transduction of extra-cellular signals to intracellular targets through membrane 
receptors9. Cross-talk between signal pathways have been reported in 
activation of estrogen-independent ER by dopamine, epidermal growth 
factor10, transforming growth factor α, insuline-like growth factor-1, heregulin, 
and cyclic AMP3 (Figure 2d). Serine residues are the predominantly modified 
amino-acids in ER, some of them being located in the amino-terminus of the 
AF-1 region (see below) like Ser-104, Ser-106, Ser-118, and Ser-16711. In 
addition, ER co-activators such as AIB1 may be subjected to phosphorylation 
by these kinase pathways12.      
Non-classical binding through AP-1
ER can activate transcription through protein-protein interactions excluding 
direct receptor binding. This can be achieved via members of the AP-1Jun/
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Fos transcription factor family together with other factors and through sites 
that bind SP1. According to Kushner13 there may exist at least two 
mechanisms by which ER can increase the activity of Jun/Fos complexes, 
depending on the ER subtype and the specific ligand used (Figure 2b). One 
hypothesis is that estrogen- or anti-estrogen-bound ERα complexes use AF-1 
and AF-2 domains  to bind to the p160 SRC component of the co-activator 
complex already recruited by Jun/Fos, triggering the co-activator pathway to a 
higher state of activity (Figure 3). An alternative mechanism suggests that 
ERß or truncated variants at the amino-terminus of ERα lacking AF-1 region, 
when bound by specific anti-estrogens/SERM, use their DBD to detach HDAC 
co-repressor complexes from Jun/Fos complexes. As a consequence, activity 
of the co-activators on these AP-1 sites becomes unrestrained.  With regard 
to the AF-1 independent hypothesis, anti-estrogens are preferred ligands at 
AP-1 sites, with the pure anti-estrogen (fulvestrant) and raloxifen being the 
most potent followed by tamoxifen, and estrogens which have almost no 
effect. In this context, the ratio of ERß/ERα in a given tumor cell may affect 
the response to tamoxifen. Moreover, tamoxifen resistance has been 
associated with increase in AP-1 activity14. 
   
     
Non-genomic signaling 
Some of the estrogen actions occur too fast to be explained by the classical 
estrogen-ER nuclear interaction since the latter takes minutes or hours. 
Evidence for a plasma membrane ER was proposed in the late seventies, 
based on studies focused on the vascular system where estrogen exert 
effects mediated in part by the endothelium-derived signaling molecule nitric 
      
Fig. 3 ER as a co-activator. Estrogen-bound ERα 
complexes use AF-1 and AF-2 domains to bind to the 
SRC component  of  the co-activator  complex already 
recruited by Jun/Fos15. 
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oxide (NO)16. Indeed, the rapid onset of estrogenic action is  due to cell-
surface moieties of ER on cell membranes, e.g. short-term vasodilatation of 
coronary arteries, the rapid insulinotropic effect of estradiol on pancreatic beta 
cells, and the rapid activation of growth-factor-related signaling pathways in 
neuronal cells3,17. This is  achieved by the presence of cell membrane ER 
localized in cell-membrane invaginations called caveolae18 (Figure 2c). From 
this  point, cell membrane ER are linked to the MAPK pathway originating a 
rapid non-nuclear effect. This has been demonstrated in osteoblasts, 
endothelial cells, neurons, and human breast cancer cells19. Furthermore, an 
estrogen-dependent interaction of membrane-bound ERα with the p85 
regulatory subunit of phosphatidylinositol 3-kinase (PI3K) induces activation of 
the PI3K/Akt pathway resulting in a rapid non-genomic activation of 
endothelial NO synthase20. This pathway has only been shown for ERα 
(Figure 4). 
Fig. 4 ER can be activated by MAPK pathways upon EGF or IGF treatment through 
phosphorylation of Ser118 at AF-1 site (un-bounded activated receptor). GFs increase the 
levels of protein kinases (phosphorilators) and decrease levels of protein phosphatases. 
Activated ER can also activate other tyrosine-kinase receptors21.
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Actions on body tissues other than breast
Estrogens stimulate growth, blood flow, and water retention in sexual organs. 
In the liver, estrogens increase lipoprotein receptors, resulting in a decrease in 
serum concentration of low-density lipoprotein cholesterol22. 
In aging skin, it increases turgor and collagen production, reducing the depth 
of wrinkles3. The rate of aromatization of androgens to estrogen in the brain is 
low, compared to other tissues, even so, local production of estrogens  was 
suggested to have neuroprotective effects: induce synaptic and dendritic 
remodeling, cause glial activation, increase density of specific receptors at the 
hippocampus, and establish synergistic action with neurotrophins3. ER is 
present in endothelial cells and smooth-muscle cells  of coronary arteries, 
where estrogens cause short-term vasodilatation and reduce vascular tonicity. 
The protective effect against atherosclerosis is  still controversial. In addition, 
estrogens increase the potential for coagulation. Estrogen deficiency 
accelerates bone loss and increases susceptibility to fractures. In fact, 
estrogens inhibit osteoclastic function acting as anti-reabsortive agents. In 
post-menopausal women with osteoporosis, bone extracts  show high levels of 
interleukin-6 and interleukin-1, which indirectly stimulate osteoclast 
differentiation.  
Actions on breast tissue
Development of the mammary gland
There is no breast development in the absence of functional ovaries and the 
premature loss of ovarian function has an important impact on reducing breast 
cancer risk. Hence, ovarian steroids are involved in both normal and abnormal 
processes. From puberty onward, ovaries secrete estradiol and progesterone 
that will act on a network of epithelial ducts leading to the formation of 
terminal end buds. It is  from these ducts ending with club-like structures that 
the terminal duct’s lobuloalveolar units  (TDLU), or lobules, are formed 
corresponding to the functional milk-producing units of the breast. Maturation 
of these lobules is initiated after menarche when alveolar ducts are 
transformed into several blind-ending, grape-like, secretory sacs, known as 
acini, alveoli, or ductules23. In breast tissue, estrogens stimulate the growth 
and differentiation of the ductal epithelium, induce mitotic activity of ductal 
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cylindric cells, and stimulate the growth of connective tissue3. However breast 
development only achieves full maturity and function during pregnancy and 
lactation. Once lactation period ends, the lobules regain the structure present 
in a non-pregnant gland but retain a larger number of individual alveoli per 
lobule than before24.   
Pathogenesis of breast cancer
According to histopathological observations, the TDLU is the site where many 
epithelial hyperplasia and carcinomas frequently arise25. Estrogens have long 
been considered as the major mitogens involved in proliferation and 
differentiation of normal human mammary epithelium and in the etiology and 
progression of breast neoplasia26,27,28. Estrogens may affect carcinogenesis 
by acting either as initiators28 (i.e. direct DNA damage by hydroxylated 
estrogen metabolites) or as promoters17 (i.e. promoting the growth and 
survival of initiated cells). More than 75% of breast tumors express steroid 
receptors suggesting they arise from the proliferative luminal cell population29. 
Consequently, the majority of breast carcinomas are invasive ductal or lobular 
carcinomas. The longer women are exposed to estrogens, either through 
early menarche and late menopause and/or through estrogen replacement 
therapy, the higher is the risk of developing breast cancer17. Furthermore, 
reduction of estrogen levels by frequent and long-term breast-feeding or by 
removal of the ovaries, especially at an early age, can dramatically lower the 
cancer risk30. In vivo studies, using human breast epithelium implanted into 
athymic nude mice have shown that epithelial proliferation is induced by 
estrogens in a dose-dependent manner, and that progesterone –either alone 
or in combination with estrogen– had no effect on epithelial proliferation31. 
However, data on the combined administration of estrogen and progestins in 
the context of hormone replacement therapy (HRT) point to an increased risk 
for breast cancer compared to estrogen-HRT alone27,32. These contradictory 
results have been attributed to different epithelial responses in pre- and post-
menopausal women. The finding that the most undifferentiated structures 
cause the most aggressive neoplasms has important implications given the 
fact that these structures are more numerous in the mammary tissue of 
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nulliparous women, who have the higher risk to develop breast cancer33. 
Moreover, studies from Russo et al show that parous women developing 
breast cancer had late full-term pregnancies or a family history of breast 
cancer34. Based on findings  that the breast architecture of nulliparous women 
is  similar to that of parous women with cancer, the authors suggest that the 
degree of mammary tissue development is important in the susceptibility to 
carcinogenesis. They also hypothesize that parous women developing breast 
cancer may have an altered/defective response to the differentiating influence 
of pregnancy hormones. Since breast cancer is an hormone-dependent 
malignancy, whose association with estrogen exposure is known since 
Beatson’s first report on oophorectomy results in 1896, it is of crucial 
importance to understand the role of the human receptor involved, i.e. the 
estrogen receptor (ER).
1.3. Estrogen Receptors
1.3.1. Discovery of ER
In 1958, during the 4th International Congress of Biochemistry in Vienna, 
Jensen reported the presence of characteristic hormone-binding components 
in estrogen responsive tissues, later called estrophiles or estrogen receptors. 
In the 50’s, enzymes were the major focus of biochemistry and, consequently, 
the scientific community supported the hypothesis that estrogen action was 
due to its metabolic change. Jensen continued his research to prove that the 
ER transformation was an important step in estrogen action and that the role 
of the hormone was to induce conversion of the receptor to a biochemical 
functional form35. More than just identifying the first hormone receptor, 
Jensen’s work was the pioneer of target therapy. Indeed, by measuring the 
binding of tritiated estradiol to ER, the receptor content was determined and 
correlated with response to endocrine ablation36. In this  study the authors 
concluded that most, but not all, patients with high levels  of ER responded to 
endocrine ablation. This information gave rise to several important lines of 
evidence concerning the potential predictive role of ER for response to 
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hormonal therapy. After the discovery of a second ER by Kuiper37 in 1996, the 
first was renamed to ERα and the second was named ERß.
1.3.2. ER protein structure 
Functional domains
ER are members  of the large super family of nuclear receptors, sharing 
similarities on the functional domains38. The human ERα protein consists of 
595 aa with an approximate molecular weight of 66 kDa. ERß is slightly 
shorter than ERα, with 530 aa and an approximate molecular weight of 55 to 
60 kDa39,38. The overall structure of both receptors is quite similar although 
the overall degree of sequence homology is low, as seen in Figure 5. 
 
Fig. 5 Similarity of domains between ERα and ERß39. AF-1, transcriptional 
ligand-independent domain; AF-2, transcriptional ligand-dependent domain.
The ER protein has 6 regions termed A to F including at least five major 
functional domains40. The amino-terminal A/B domain contains  a hormone-
independent transcription activation function (AF-1) that can stimulate 
transcription in the absence of hormone binding. AF-1 is also thought to be 
responsible for gene and cell specificity and to be important for the agonist 
activity of SERMs probably through phosphorylation of specific serine 
residues41. It has therefore been proposed that AF-1 domain may be involved 
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in hormone resistant breast cancer42. The AF-1 activity of ERß is  neglectable, 
a fact that supports differences in transcriptional activation since SERMs (e.g. 
tamoxifen) exert solely an antagonistic effect through ERß43. The C-domain is 
highly conserved among the nuclear receptors and is the site for DNA binding 
(DBD). ERß is  reported to have 95-97% homology with ERα in the DBD39. 
This  site contains nine cysteines in fixed positions that are arranged in two 
zinc fingers. Hormone binding induces conformational changes that allow the 
receptor to bind to ERE present in target genes. Moreover, these zinc fingers 
are also involved in receptor dimerization3. The high degree of homology 
between the DBD of the two ER subtypes suggests that both bind to ERE and 
that they can heterodimerize44. Region D is  the hinge domain, which appears 
to function as a site of rotation, and may be an important binding site for 
accessory proteins. A nuclear localization signal, responsible for the nuclear 
localization of ER, also resides in this  region. ERß has only 30% of homology 
with ERα at this region. Region E is the ligand-binding domain (LBD) and the 
degree of homology between both ER subtypes is 55%. Structural studies of 
the ER LBD suggest that the binding pocket for the ligand is nearly twice the 
volume of estrogen45. It has been proposed that this feature may be related to 
undiscovered endogenous ER modulators. Crystallography studies with 
different ligands of the ER have revealed that the structural and 
conformational changes induced by various ligands contribute to their agonist 
versus antagonist effects46. A key event is the repositioning of helix 12 (H12) 
of the LBD in the presence of an agonist, such as estrogen, to seal the steroid 
in the hydrophobic pocket, allowing the ER complex to recruit co-activators to 
the transcriptional complex on the surface of H1238,47. With antagonists like 
raloxifen, H12 realignment is prevented by a bulky side-chain which protrudes 
from the ligand pocket and cause H12 to rotate away from an agonist position. 
Hence, H12 and its high degree of mobility in the presence of different 
ligands, illustrates the major functional element of the estrogen receptor. 
Furthermore, the low degree of homology between ERα and ERß within the 
LBD, together with their different tissue distribution, suggests  that the two 
receptors act selectively and adjust different responses with distinct 
physiological roles48. Region E contains another trans-activation function, 
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named AF-2. In contrast to the AF-1 domain at the A/B region, AF-2 requires 
an agonist ligand for its  activity. Moreover, it is highly influenced by the 
proportion of co-regulatory proteins within a given cell38. ERß lacks most of 
the carboxy-terminal F domain of ERα with only 26 aa. This region seems to 
have specific regulatory functions affecting the agonist/antagonist balance of 
certain anti-estrogens49.
ERα isoforms
From the seven known ESR1 promoters, A to T give rise to transcripts 
differing at the 5’-untranslated region (5’UTR) as  a consequence of alternative 
splicing to a common accepter splice site at exon 150,51 (Figure 7). These 
mRNAs are translated into the 595 aa full-length ERα protein also called 
ERα66. A spliced variant (ERα46) originates from promoters E and F and 
uses an alternative splicing acceptor site at exon 2, but not at exon 152,50,53. 
As a consequence, this amino-terminal truncated product of ERα66 lacks the 
A/B domain and is expressed in plasma membrane, cytosol, and nucleus of 
resting, estrogen deprived cells52. In bone, a tissue ERα46 specific variant is 
up-regulated by estradiol in the absence of an ERE consensus at promoter 
F54. The splicing of DNA sequences from promoter E generates a mRNA 
unique 5’UTR that may potentially allow for liver-specific regulation55. The 
ERα46 truncated protein has been located at discrete compartments of the 
plasma membrane, known as caveolae from where a cross talk to alternative 
ER pathways is initiated56 as shown in Figure 2c.
ERß isoforms
The wild-type ERß1 encodes the full-length 530 aa receptor protein, as a 
result of complete ESR2 exon 8 transcription57. The ERß2, also called ERßcx 
(for C-terminal exchange), differs  from the former at the alternative exon 8, 
encoding for a C-terminal truncated ERß protein with 495 aa44. Recently, the 
ERß5 isoform was identified giving rise to a truncated ERß5 protein with 472 
aa in length whose upstream sequence was  only recently reported. According 
to Ramsey et al57 transcriptional differences between ERß isoforms and ERα 
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depend on the ERE sequence, which confirms that the DNA sequence bound 
by ER is an allosteric effector of ERs action. Consequently, the cellular 
expression of ERß isoforms may differently impact ERE-regulated target gene 
expression in a ligand-dependent manner. 
Fig. 6 ERß protein isoforms: the 8th variable exon is translated into different carboxy-ends of 
ERß proteins, the full-length ß1, and amino-truncated ß2/bcx, ß3, ß4 and ß5 proteins58.
Indeed, ESR2_ß1 is  the only fully functional receptor in the ERß family 
because it displays  high estradiol binding affinity, homodimer formation, 
SRC-1 co-activator interaction, and ligand dependent transactivation59. 
ESR2_ß2 and ESRß5 isoforms have no intrinsic transactivation activity 
because they cannot form homodimers due to the weak or absent LBD, and 
they are unable to recruit co-regulators, as a result of lack of helix 12 of the 
ESR2_ß5 isoform or shrinkage of the co-regulator binding cleft of 
ESR2_ß259,60. As a consequence, ESR2_ß1 is the “obligatory partner” of a 
functional dimeric complex, while ESR2_ß2 and ESR2_ß5 are variable dimer 
partners and serve as enhancers. 
Relative binding affinities for ER
Due to the low degree of homology between the receptors  at the LBD, some 
ligands bind to the two ER with different affinities3. While the binding affinity 
for 17ß-estradiol is similar, estrone has higher affinity for ERα. On the other 
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hand, ERß appears to have higher affinity for phytoestrogens. The latter are 
naturally occurring non-steroidal plant compounds having structural and 
functional similarities to estrogens. Their main characteristic is  to possess a 
phenolic ring as an indispensable feature for ER binding. Isoflavonoids such 
as genistein and daidzein have been the most studied group. Genistein 
inhibits steroidogenic enzymes as well as tyrosine kinase enzymes. The 
SERM raloxifen binds with higher affinity to ERα, whereas pollutants  like 
alkylphenols have a higher affinity for ERß. According to Jordan et al61, the 
relative affinities for ERs in descending order are: 4-hydroxy-tamoxifen, 17ß-
estradiol, tamoxifen, N-desmethyl-tamoxifen17.  
1.3.3. ER genes: ESR1 and ESR2
ERs belong to the nuclear receptor superfamily of transcription factors. 
Estrogen effects are mediated by two ERs, the ERα (NR3A1) and the ERß 
(NR3A2)37. The two receptor subtypes, often addressed as  isoforms, are 
indeed not isoforms of each other, but represent distinct proteins (ERα and 
ERß), encoded by different genes (ESR1 and ESR2, respectively) which map 
to distinct chromosomal loci (6q25.13 and 14q22-2462, respectively). 
ESR1 gene
The human ERα cDNA was cloned in 198663. ERα is encoded by the 
estrogen receptor 1 (ESR1) gene that consists of 8 exons spanning 140Kb of 
chromosome 6 (Figure 7). It contains 7 known promoters  designated as A to 
F, and T related to a transcript identified in testis. Transcripts differ at the 5’-
untranslated region (5’UTR) as  a result of alternative splicing to a common 
acceptor splice site at exon1, giving rise to several mRNA transcripts64. 
Transcripts from promoters  E and F are spliced to exon 2, giving rise to an 
amino-terminal truncated ERα protein lacking exon 1 (see ERα isoforms). 
Most of the ESR1 promoters have no TATA-CCAAT-box, or GC box 
sequences, which leads to multiple transcription start sites. According with 
transient transfection experiments, ESR1 promoters are rather weak when 
compared to other promoters, for example, promoters  A, F and T are 100 to 
1,000-fold weaker than the human Glyceraldehyde-3-phosphate 
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dehydrogenase promoter64. Consequently, the low transcriptional activity of 
the ESR1 promoters ensures that low levels  of ERα protein are expressed in 
the cell. 
Fig. 7 ESR1 gene annotation of the seven promoters (A to T) and eight exons (CDS). Gaps 
between exons corresponds to intronic areas. ATG corresponds to the initiation of translation 
(+234) and the yellow triangle represents the common acceptor splice site (+163). Adapted 
from reference 64. 
On the other hand, the presence of multiple promoters rather than a single 
tightly regulated one has been addressed from three different main 
perspectives: i) Different tissues make use of different promoters, ii) Different 
promoters are used in different stages of development, iii) Different transcripts 
from distinct promoters result from alternative splicing events that originate 
different protein isoforms. In the case of ESR1 there is  evidence about the 
specific tissue expression of the different transcripts or mRNA isoforms. 
Although there is an agreement on the multiple promoter usage by the ESR1 
gene, there is  uncertainty on the contribution of each promoter to ERα 
transcription and translation. In the normal mammary gland promoter A usage 
is  dominant, whereas ERα over-expression in tumors has been attributed to 
promoter C formerly designated promoter B65.
ESR2 gene
ERß protein is  encoded by the ESR2 gene, discovered in 199637 and cloned 
the year after62. Compared to ESR1 with translated exons spanning more 
than 140 kb, ESR2 is smaller spanning approximately 30-40 kb. Two major 
transcription start sites were identified, located 43 Kb apart, with the 5’ 
transcription start site being approximately 400 bp upstream from the ATG 
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translation initiation site66 (Figure 8). Transcripts differing at the 5’UTR were 
transcribed from these two different promoters, named promoter 0K and 0N67. 
Fig. 8  ESR2 gene: promoters 0K and 0N drive two transcription start sites giving rise to 
mRNA differing at the 5’UTR. Exons are interrupted by intronic  regions. Exon 8 is variable in 
length according to the ERß isoform. Adapted from reference 67.
The proximal promoter (0N) contains both TATA box and Inr element. ESR2 
encloses 8 exons that are translated in different protein isoforms, differing at 
the C-terminus as a result of variations at the last 8th exon. The distinct 
sequences at exon 8 are therefore specific for the respective isoform. Li et 
al66 have also identified a negative regulatory region element located at -425 
bp. This region is a ubiquitous transcription silencer that represses 
transcription in the absence of steroids. In addition, an Alu sequence at the 
distal 5’-end of the distal promoter (0K) seems to contain an ER-dependent 
enhancer element with an imperfect ERE-related palindrome66. It has been 
suggested that estrogens make use of this enhancer element to regulate ERß 
expression. According with Leygue et al68 who studied mRNA expression of 
the three main ERß isoforms, ERß2 and ERß5 expression levels are superior 
to ERß1 in some breast tumors, while the latter being the main isoform in 
normal breast tissue. On the other hand, ERß2 protein expression increased 
from normal to breast cancer, showing high levels of expression in some 
tumors irrespectively of the ERα status67. Furthermore, total ERß expression 
was lower in cancer than in normal breast tissue. This  fact has supported the 
hypothesis that ERß might act as a TSG69.
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1.3.4. Expression of ER subtypes
Tissue distribution 
Although there is some overlap on the tissue distribution of ERα and ERß, the 
tissue specific expression differs. ERα is the dominant receptor present in 
endometrium, breast cancer cells, and ovarian stroma. The ERß has a 
broader distribution showing expression in non-classic target tissues  such as 
kidney, thymus, intestinal mucosa, lung parenchyma, spleen, blood 
leukocytes, bone marrow, bone, brain, endothelial cells, uterus and prostate 
gland3,62. In the ovary, ERß is localized to the stroma of the cortex and in 
blood vessels  of the medulla. Moreover, granulosa cells and developing 
spermatids contain mainly ERß.
Expression in mammary cells 
In normal mammary epithelial cells, the level of ERα fluctuates in function of 
the cyclical changes of estrogens  during the menstrual cycle. ERα is 
expressed in luminal epithelial cells but not in myoepithelial or stromal cells of 
the human breast70,71. Around 50-60% of the pre-menopausal breast 
epithelium expresses ERα rising to approximately 80% in post-menopausal 
women72. In contrast, ERß is detected at high levels  (85%) in the normal 
breast, in both luminal and myoepithelial compartments73. In addition, ERß is 
expressed in both fibroblast-like and endothelial cells, where ERα is not. In 
parallel, the Ki-67 labeling index reveals that the proliferation fraction of breast 
epithelial cells usually does  not express ERα or PgR. Hence, rarely the ERα-
positive cells are Ki-67 positive71,74. This suggests that secretion of growth 
factors by the steroid receptor-containing cells stimulates the division of 
adjacent division-competent cells in a paracrine way74. Differently, in breast 
cancer, ERα-positive cells are also proliferating which supports the presence 
of an autocrine regulation in which the cells respond to self-secreted growth 
factors75 .   
1.3.5. Methods for ER assessment 
Information about the ER-status has been a useful tool to identify the group of 
patients with higher probability to respond to endocrine treatments such as 
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anti-estrogens i.e. to be a predictive factor. In addition, tumors expressing ER 
are considered to be estrogen responsive, and have a biological less 
aggressive behavior, that is, ER is a prognostic factor. The first standard 
method for ER detection was the ligand-binding assay (LBA) from which the 
prototype dextran-coated charcoal (DCC) radioactive method was the most 
commonly used. The suspension of charcoal in dextran solution is  added to a 
mixture of tumor extract with radioactive and non-radioactive estrogen to 
create two-phases: bound and not bound. When receptors are present, the 
radioactivity detected within the bound fraction diminishes continuously with 
increase mass of non-radioactive estradiol76. Receptor activity was reported in 
70% of human breast cancers tested and in 21% of benign breast tissues. 
The drawbacks of this reproducible quantitative assay for ER determination 
are the need of large amounts  of tissue (heterogeneous mixture of tumor and 
normal tissue), the false-negative results originating from exogenous or 
endogenous (pregnancy) sources of hormones, and the usage of radioactive 
material77. The development of antibodies  against specific ER epitopes made 
it possible to explore new methods such as immunohistochemical assays 
(IHC). The latter is based on the localization of antigenic epitopes  or proteins 
in tissue sections by the use of labeled antibodies as specific reagents 
through antigen-antibody interactions that are visualized by a marker such as 
fluorescent dye, enzyme, or colloidal gold. Given the advantages of avoiding 
the manipulation of radioactivity and of using less tissue, independently of 
being fresh or formalin fixed paraffin-embedded tissue, this methodology soon 
became practice78,79. Even more, the requirements  of small tissue samples 
were fulfilled by fine needle aspirates and core biopsies, allowing to monitor 
ER-status during therapy. Equally important is  the possibility to detect the 
receptor independent of its functional occupancy and to relate the receptor 
content to morphology. In summary, the simplicity and low cost of IHC using 
monoclonal AB emerged as an appealing assay for routine diagnostic 
procedures. In line with this  evidence several studies were initiated in order to 
compare both techniques, DCC and IHC assays78,41,77. Overall, the degree of 
correlation of ERα levels estimated by the two different methods was 
considered good (r = 0.68 to 0.73), supporting their use to evaluate ERα-
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status in breast cancer. To ensure consistency of results in clinical practice the 
European Working Group for Breast Screening carried an inter-laboratory 
study within the European Union80. Results showed that in the evaluation of 
ERα-negative tumors as well as in that of strong ERα-positive ones, there 
was an excellent concordance among laboratories; however, the same did not 
happen in tumors with moderate to low levels of ERα80. Corroborating these 
results, an older study involving 26 countries and 200 laboratories reported 
that only 37% of laboratories scored adequately ERα-low expressing 
tumors81.  
In fact, the IHC analysis includes different steps prone to lack standardization 
e.g. tissue fixation (type, temperature, duration), efficiency of antigen retrieval, 
detection system, specificity of the primary AB, and scoring system82. 
Nevertheless, for clinical use, and in the absence of a more reproducible 
assay, IHC predicts better than LBA the response to anti-estrogens in the 
adjuvant setting. 
1.4. Molecular regulation
1.4.1. Epigenetic regulation
Epigenetics is related to a stable alteration in gene expression without 
interference in gene sequence83. These alterations occur during development 
and cell proliferation. One of the most studied epigenetic modifications is 
hypermethylation, which represses transcription of the promoter regions of 
tumor suppresser genes. This so-called aberrant gene silencing in cancer 
through gene promoter methylation has been associated to initiation and 
progression of neoplasia84. In contrast to normal cells, cancer cells exhibit a 
shifted methylation pattern rarely showing methyl-covalent modifications at 
cytosine-phospho guanine (CpG) sites outside the promoter regions, but a 
gain of methylation within DNA stretches of CpG clustered sites known as 
“CpG islands” at the promoter regions85. The reasons why DNA 
methytransferases fail to methylate at the expected sites and have increased 
sensitivity to do it at the promoters are not fully understood. However, de novo 
methylation occurs early in tumorigenesis84,83 and is  associated with ERα 
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expression loss during malignant disease progression55,86. Methylation is 
known as a reversible physiological gene silencing mechanism catalyzed by 
DNA methyltransferases (DNMT) which –in humans and most mammals- add 
methyl groups (CH3) to the fifth carbon of the cytosine ring at CpG sites 
creating methyl-cytosines (5mC)85. The mechanism leading to the ultimate 
transcription repression emerges from the combined influence of DNMT and 
recruited histone deacetylases (HDAC), which interact physically to form 
transcriptionally inactive chromatin structure. This mechanism was previously 
reported for ESR1 silencing in endometrial87 and breast cancer88. 
1.4.2.  Regulation by transcription factors
ER expression has  been attributed to transcriptional regulation by 
transcription factors such as ER factor 1 (ERF-1) and ER-B factor 1 (ERBF-1), 
which transactivate promoter A and promoter C (previously called B), 
respectively. Importantly, upon demethylating treatment no transcription was 
seen from either one of the promoters in the absence of the mentioned 
transcription factors55. In fact, ERα-negative cell lines like MDA-MB-231 do 
not express  any of the transcription factors, and consequently the 
demethylation treatment was not sufficient to induce transcription. Hence, re-
expression of ERα may be prevented in a context of absence of these 
transcription factors88.       
1.4.3. ER regulation by estradiol
Estradiol-induced ERα turnover mediated by the ubiquitin ligase 26S 
proteasome systems has been reported as part of the estrogen signaling 
pathway55.  Proteasome-dependent down-regulation of ERα was observed in 
vascular endothelial cells  in response to estradiol and was followed by the 
transcriptional activation of ESR1 and the repletion of ERα protein levels at 6 
hours89. These results indicate that acute degradation of ERα followed by an 
estradiol-dependent transcriptional activation of ESR1 is a general estradiol 
response. Moreover, as stated by Pinzone et al55, most studies showed that 
estradiol maintains these tissues  in an estrogen-responsive context by up-
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regulating steady-state ERα expression levels. The alternative promoter 
usage regulates transcription of ESR1 in a tissue specific allocation of ESR1 
transcripts such as  the liver-specific regulation by transcripts driven by 
promoter E90 or the bone-specific regulation by transcripts driven by promoter 
F91. Increased degradation of ligand-bound ERα occurred via ubiquitination 
and 26S proteosomal degradation pathways in response to the pure estrogen 
antagonist fulvestrant, estradiol, and the SERM 4-hydroxytamoxifen in a 
decreasing ranking order. It is of note that fulvestrant fails to elicit a 
compensatory stimulation of ESR1 transcripts, a situation that causes 
sustained depletion of ERα in breast tumor cells92.   
 
1.5. Hormonal therapy
Breast cancer is an endocrine-dependent disease mediating estrogen 
mitogenic effects through ER38. This knowledge has been exploited clinically 
with endocrine treatments that seek to perturb the steroid hormone 
environment of the tumor cells. Consequently, hormonal therapy targets ER 
signaling pathways using different mechanisms: 1. Competitive binding to ER 
e.g. SERMs and pure anti-estrogens; 2. Down-regulation of ER e.g. pure anti-
estrogens; and 3. Reduction of estrogen levels e.g. oophorectomy, ovary 
suppression by LHRH agonists, and aromatase inhibitors (AI). 
1.5.1. SERMs
The term SERMs i.e. selective estrogen-receptor modulators define synthetic 
non-steroidal compounds that compete with estrogen in ER binding, inhibiting 
its action in tissues like breast and uterus, and mimic estrogen action in others 
such as  bone, brain and cardiovascular system3. The estrogen-like agonistic 
effect in bone and cardiovascular system or brain is beneficial for women 
since it maintains bone density and function, respectively. Hence, SERMs are 
generally mixed antagonist/agonist ligands for ER. The mechanism of the 
tissue selectivity of SERMs is complex. The conformation of the LBD changes 
depends on the ligand (e.g. estradiol, tamoxifen, raloxifen, or genistein) bound 
to ERα and ERß. This re-organization of a major transactivation domain 
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(AF-2) is such that a different binding surface is exposed to nuclear-receptor 
co-regulators, i.e. co-activators or co-repressors38 (Figure 9). 
Fig. 9 ER tissue specific  effects according to Jordan et al38 hypothesis: In the presence of a 
pure antagonist, ER is stabilized in the inactive conformational state and binds co-repressor 
tightly. In the presence of a pure agonist, it acquires a fully active conformation and binds co-
activator tightly. In the presence of a mixed SERM, the receptor adopts an intermediate partial 
conformation being even more subject to interactions with the relative intracellular 
concentrations of co-activators or co-repressors for its activity. 
In addition, the specific sequence of EREs and the cell signaling context are 
complementary events influencing the action of SERMs38. This model was 
studied in detail by x-ray crystallography, revealing a carboxy-terminal tail of 
the receptor (H12) acting as a lid of the ligand pocket that, in turn, attracts 
newly recruited co-regulators46. Most of the co-regulators are enzymes that 
participate in remodeling the local chromatin structure at the target promoter, 
initiating transcription by RNA polymerase, enhancing efficient elongation of 
RNA chain synthesis, regulating alternative RNA splicing, and lastly, 
destroying the active transcription factors at the promoter site93. This 
transcriptional chain of events occurs in a sequence of 15 seconds apart, 
directly controlled by the sequential occupation of the promoter by specific co-
regulator complexes. These are regulated post-translationally with intracellular 
concentrations determined by their proteasomal degradation rates38. Thus, 
receptor conformation is depending on local concentrations of activated co-
activators and co-repressors. Since co-activators are usually activated by 
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phosphorylation and monoubiquitylation, inactivated by SUMOylation and 
degraded after polyubiquitylation, the status  of the cell signaling pathways 
generating these post-translational modifications is a major complementary 
modulator of SERM action94.       
Tamoxifen and raloxifen
Tamoxifen (ICI 46474), considered the first prototypic SERM, was discovered 
in the laboratories  of Imperial Chemical Industries (ICI) Pharmaceuticals 
division as an antiestrogenic trans isomer, with the intent of designing a drug 
with post-coital contraceptive effects. However, unlike the results observed in 
rat, tamoxifen was not a contraceptive in humans, but quite the opposite95. 
Close to be abandoned as an orphan drug, tamoxifen was re-invented by 
Jordan in the seventies under Walpole support, to become the first target 
therapy for the treatment and prevention of breast cancer95. Initially, the 
advantage of tamoxifen was the low incidence of side effects but the key for 
its success in the prevention of breast cancer in high-risk pre- and post-
menopausal women was a sustained duration of action and its characteristic 
long-term effect even after the therapy is stopped96,97,98. Meanwhile, from the 
collected follow-up data, its specific actions were clarified showing that 
tamoxifen exhibits  antagonist activity in the breast accompanied by undesired 
agonist activity in the uterus. In fact, the incidence of endometrial cancers 
increases from one to four per 1000 post-menopausal women per year99. With 
the intention of developing an evidence-based therapeutic strategy, a second 
generation of SERMs that reduce the risk of breast cancer, prevent 
osteoporosis and does not increase incidence of endometrial cancer became 
available with raloxifen38. The comparison of tamoxifen and raloxifen was 
initiated in a large chemopreventive clinical trial named Study of Tamoxifen 
And Raloxifen (STAR) involving 19,471 high-risk post-menopausal volunteers. 
Results of STAR showed that the drug raloxifene is  as  effective as tamoxifen 
in reducing the breast cancer risk of the women on the trial. In STAR, both 
drugs reduced the risk of developing invasive breast cancer by about 50 
percent. In addition, within the study, women who were assigned to take 
raloxifene daily and who were followed for an average of about four years had 
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36% fewer uterine cancers and 29% fewer blood clots than the women who 
were assigned to take tamoxifen. Raloxifen had no effect on DCIS or LCIS 
incidence100. 
Importantly, the understanding of tamoxifen’s pharmacology has supported 
the development of SERMs, AIs and pure anti-estrogens101. 
1.5.2. Pure anti-estrogens and AIs
Pure anti-estrogens (such as fulvestrant) destroy the ER in tissues while AIs 
(such as the 3rd generation anastrozole, letrozole and exemestane) inhibit 
peripheral tissue and tumor cell conversion of adrenal androgens to estrogens 
in post-menopausal women101,102. These drugs have been shown to be 
effective treatment of breast cancer and to be superior to tamoxifen in some 
clinical studies, namely Anastrozol, Tamoxifen Alone or Combined (ATAC)103. 
In fact, the last ATAC analysis at 100 months follow-up (8,5 years) reveals  that 
anastrozole has a carryover effect with benefits enduring after the 5 years of 
treatment as follows: 25% reduction on recurrence rates and 16% reduction 
on distance recurrence. However, the bone mineral density loss is  manifested 
as an increase of 50% of fracture rates  during treatment and 7% increase of 
arthralgia compared to tamoxifen (ASCO2008). In spite of the suggested AIs 
safety, following the report of no increase on bone fracture rates after the end 
of the treatment, fracture rates during treatment are a source of morbidity and 
decrease on quality of life. The usage of biphosphonates, inhibitors  of bone 
absortion by osteoclasts, constitutes the option to block this inherent side 
effect but with enormous increase in cost preventing its applicability 
worldwide. Furthermore, the long term physiological consequences of 
estrogen deprivation, with AIs, and ER destruction, with pure anti-estrogens, 
are still to be evaluated, particularly with respect to coronary heart disease 
and central nervous system side effects101.    
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1.5.3. Resistance mechanisms
There are three main mechanisms of resistance to tamoxifen: 1) metabolic 
resistance, i.e. the patient’s  own metabolic capacity can influence tamoxifen 
efficacy; 2) intrinsic resistance, i.e. albeit tumors expression of ER, still they 
are resistant to tamoxifen; 3) acquired resistance, i.e. initially responsiveness 
to tamoxifen followed by recurrence (Figure 10).   
 
                             Fig. 10 Possible types of drug resistance to SERMs           
                             action, particularly tamoxifen38.
Metabolic resistance
Tamoxifen metabolic bioactivation was recognized during the 1970s by Jordan 
et al, when the first potent anti-estrogen metabolite 4-hydroxy-tamoxifen was 
described104. The latter has 100-fold greater affinity to ER and is 30- to 100-
fold more potent in suppressing estrogen-dependent cell proliferation than the 
prodrug tamoxifen. Endoxifen (N-desmethyl 4-hydroxy-tamoxifen) was 
identified in the late 1980s, but its  biological activity and its  role in the 
biotransformation of tamoxifen was only recently characterized by Desta et 
al105. Indeed, they have shown that endoxifen has equivalent potency to 4-
hydroxy-tamoxifen, both in terms of binding affinity to ER and suppression of 
estrogen-dependent proliferation of breast cancer cells. It is exclusively 
formed via 4-hydroxylation of the primary tamoxifen metabolite, N-
desmethyltamoxifen, by the CYP2D6 enzyme. In the general population there 
is  a great genetic variability of the CYP2D6 enzyme which potentially 
      
47
influences drug metabolism. Women carrying impairing variants  of the 
CYP2D6 enzyme have reduced plasma concentrations of endoxifen. Goetz et 
al106 provided the first clinical evidence between endoxifen and tamoxifen 
response concluding that the CYP2D6 *4 variant allele was an independent 
predictor of a higher risk of relapse and a lower incidence of hot flashes in 
postmenopausal women. On the one extreme, functional CYP2D6 is replaced 
in some 5-10% of individuals of European descent by a non-functional 
genotype, that is, individuals homozygous for e.g. CYP2D6 *3, *4, or *5, are 
predicted to be poor metabolizers. Patients with these phenotypes are 
supposed to be unable of tamoxifen bioactivation to endoxifen, and 
consequently, may have decreased, or abolished, anti-estrogenic effect of 
tamoxifen38. More generally, CYP2D6 phenotypes have been divided in four 
metabolic classes: poor metabolizers (PM), intermediate metabolizers  (IM), 
extensive metabolizers (EM), and ultrarapid metabolizers  (UM). Over eighty 
different single nucleotide polymorphisms have been identified104 so far. 
Importantly, Schroth et al107 in our group at IKP reported that women with 
CYP2D6 reduced-function alleles experienced significantly more recurrence, 
shorter relapse free time, and shorter event-free survival in breast cancer 
patients treated with tamoxifen. Hence, women belonging to the group of PM 
may benefit from AI ab initio.
Intrinsic resistance
In general, breast cancer patients expressing ERα and PgR in their tumors 
respond to anti-hormonal therapy in 70-80% cases, while patients expressing 
ERα but not PgR respond only at a rate of 34-40%17,108. Response rates of 
45% are seen in patients  with ERα-negative but PgR-positive tumors17. The 
predictive value of PgR expression is  likely related to the ability of estrogens 
to induce its  expression in a functional ER signaling pathway. In this context, 
the signaling via the human epidermal growth factor receptor 1 (HER-1; 
EGFR) pathway enhances paracrine growth factor stimulation and impairs 
estrogen induction of PgR in breast cancer cells. Altogether, the effectiveness 
of anti-estrogen treatment at the ER is diminished. Moreover, as shown in 
experimentally engineered breast cancer cells, high levels  of the HER-2 
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growth factor receptor and the co-activator SRC3 (AIB1) result in an agonist 
activity of tamoxifen109. Hence, intrinsic tamoxifen resistance has been 
associated with tumors  expressing HER-2, ER but not PgR. It has been 
suggested that this phenotype is also more likely to respond to AI79.
 
Acquired resistance
In vivo experiments in athymic mice, with ER-positive, PgR-positive breast 
tumor phenotype showed that continuous tamoxifen exposure gives  rise to 
tumors growing in response to either tamoxifen or estradiol38. In contrast, the 
absence of treatment or the treatment with AI inhibits  tumor growth, which 
specifically mirrors  the clinical situation when patients fail to respond to 
tamoxifen. This is  in fact what clinical experience has shown in patients that 
fail to respond to tamoxifen and get switched to AI treatment. The hypothesis 
that the failure of the transduction pathway may be circumvented by switching 
to alternative drug prescriptions that prevent tumor growth by blocking the 
patient’s capacity to synthesize estrogens, has been reported in several 
clinical trials110. Given the inverse association between ER and EGFR 
expression, it has been suggested that anti-hormonal intervention that deprive 
breast cancer cells from estrogens may consequently promote expression of 
EGFR, a phenomenon eventually culminating in the development of an 
acquired endocrine resistant phenotype111. In this  context, clinical and 
experimental data provide evidence that these cells rarely lose ERα 
expression, a situation that differs from the 20-30% relapsing tumors which 
display an ERα-negative, EGFR-positive endocrine unresponsive phenotype 
at diagnosis111. In addition, tumor co-expression of EGFR and HER-2 appears 
to be associated with particularly aggressive phenotypes showing poor 
prognosis and resistance to endocrine treatment. This may be a result of the 
formation of heterodimeric receptor complexes that acquire a highly efficient 
mechanism to transmit its mitogenic signals  (Figure 11a) and escape the 
growth restraints of endocrine therapy. Patterns of expression of the HER/
erbB family members may vary dramatically following long-term anti-hormonal 
exposure and it is likely that these changes in receptor patterns are a general 
feature of acquired endocrine-resistant state112. Furthermore, increased 
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expression of TGFα in clinical breast cancer specimens has been related to 
primary endocrine insensitivity in ERα-positive disease with increased growth 
fraction as  monitored by Ki67 immunostaining113. Moreover, acquired 
resistance to tamoxifen in vitro is  accompanied by increases in IGF-I binding 
in MCF-7 cells114. Similar changes occurred in vivo in elements of the IGF 
signaling pathway and that contributes to the acquired resistance 
phenomenon in the clinic. Indeed, membrane-bound receptors for insulin-like 
growth factors, and their ligands IGF-I and IGF-II are more potent mitogens 
for human breast cancer cells than TGFα or EGF10. Increased activation of 
MAPK has been associated with shorter duration of response as well as  with 
reduced survival time in ERα-positive tamoxifen treated breast cancer 
patients115. This is substantiated by MAPK inherent capacity to influence AP-1 
and ERK1 signaling, and to activate the ERα, through phosphorylation on 
Ser-118 at A/B domain (Figure 11b). Endocrine resistance may arise from 
altered ERα phosphorylation patterns influencing its transcriptional activation.   
    
    a
Fig. 11a  Members of a family of membrane receptors known as the HER family, which 
includes HER1 (EGFR or c-erbB), HER2 (c-erbB2), HER3, and HER4. All of the receptors 
have tyrosine kinase activity except HER3. These receptors have different binding affinities: 
TGFα and EGF are the two most important ligands for EGFR; NRGs (neuregulins) are 
important factors for HER3 and HER4; HER2 is an important signaling partner of EGFR and 
functions as a co-receptor. Upon binding and dimerization, the tyrosine kinase transfers a 
phosphate to a tyrosine residue on the intracellular domain of the receptor, thereby initiating 
the signal  transduction pathway116, 11b Cell surface receptors bind ligands that activate the 
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receptor and regulate cell functions. In this example, EGFR can bind EGF as well as several 
other ligands. Upon dimerization, the intracellular tyrosine kinase domains of the receptor 
transphosphorylate the dimers, initiating a signal cascade with subsequent transduction of the 
signal to the nucleus and regulation of genetic functions117.
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Chapter 2. Study Aims 
ERα is the most important therapeutic target in breast cancer. At the time of 
diagnosis  about 75% of breast tumors show ERα protein expression118. 
Current ER targeting endocrine strategies include the induction of structural 
changes with SERMs such as tamoxifen, degradation of ERα with selective 
down-regulators such as fulvestrant, and inhibition of estrogen synthesis  with 
AIs such as anastrozole and letrozole, any of which result in a substantial 
decrease of tumor growth38. According to the St. Gallen’s  Consensus, breast 
cancers are divided into endocrine responsive, endocrine non-responsive, 
and endocrine response uncertain119. Therefore, the assessment of a tumor’s 
ERα-status represents  the basic step towards decision making on hormonal 
therapy. In contrast, few data thus  far exist for the pathophysiological role of 
the ERß sub-type. The standard routine diagnostic procedure worldwide is the 
IHC detection of the ERα immunogenic epitope followed by the combined 
scoring of stained cells and staining intensity. For tamoxifen, ERα-status 
guided endocrine treatment succeeds to control the disease in nearly 50% of 
ERα-positive pre-120 and post-menopausal121 patients. The lack of treatment 
response in the remainder however waits clarification. There is an ongoing 
debate, whether methodological limitations including lack of specificity of the 
primary antibody and standardized scoring, as well as inter-laboratory 
variations122 may hamper correct treatment decisions due to incorrect ERα 
protein assessment. False negative detection rates have been reported for 30 
to 60% cases, particularly for patients with low ERα levels123. It is  therefore of 
crucial interest to clarify whether the assessment of ER expression (both sub-
types), using measurements other than the protein level may aid in the 
distinction between patients likely to benefit from endocrine treatment from 
those who require alternative treatments. 
ESR1 is  a large gene with more than half of its  extension being non-coding 
sequences with multiple promoters  separated by large segments 
inbetween124. Multiple promoter usage and alternative splicing mechanism 
suggest a complex regulation of differently expressed transcripts within 
different tissues and for distinct physiological stages. Since SERMs exert 
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agonist/antagonist effects in different tissues, there is a possibility that the 
study of distinct mRNA transcripts along with putatively underlying molecular 
mechanisms, may elucidate aspects of SERM resistance patterns, particularly 
to tamoxifen. On the other hand, the large distance between promoters 
suggests epigenetic regulation of promoter dependent isoforms, as gene 
silencing usually involves large genomic regions. 
The present study was designed to address the questions whether ESR1 and 
ESR2 selective mRNA expression levels and promoter cytosine-
phosphoguanine (CpG)-methylation may improve ERα assessment in breast 
cancer and consequently may provide better classification tools  for variable 
response to tamoxifen. These questions have been addressed in detail as 
follows:
• Is ERα a valid prognostic classifier?
• Does ERß contribute to ER signaling and prognosis?
• Do molecular profiles  (mRNA expression) of ER regulation and downstream 
signaling contribute to a better understanding of tamoxifen resistance?
• Is there a relevant role for different ER promoter usage in breast cancer? 
• Is the ER promoter methylation status predictive for ER protein level in the 
tumor?
• Are ER isoforms functionally distinct at the level of ER regulation?
• In which way do genetic and epigenetic factors contribute to tamoxifen 
outcome?
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Chapter 3. Patients and Methods
3.1. Patients’ samples 
This  study was performed using formalin-fixed paraffin-embedded tissue 
specimens from 211 patients with breast cancer archived at the Pathology 
Department of Robert Bosch Hospital, Stuttgart, Germany. Patients and tumor 
characteristics are given in table 1.
Characteristics
Patients
No. %
Age, years (median 61.3)
≤ 49
≥ 50
33
178
15.6
84.4
ER (IHC)
Positive 150 71.4
Negative 60 28.6
PgR (IHC)
Positive 145 70.4
Negative 61 29.6
Grade
1 10 4.8
2 147 70.3
3 52 24.9
Tumor size, cm
< 2 82 39.0
2-5 87 41.4
> 5 41 19.6
Nodes
0 107 54
1-3 82 41.5
4+ 9 4.5
Stage 
I 62 30.2
II 109 53.2
III 28 13.7
IVa 6 2.9
Tamoxifen-adjuvant
Yes 148 70.1
No 51 24.2
n.a.a 12 5.7
Chemotherapy-adjuvant
Yes 44 20.9
No 162 76.7
n.a. 5 2.4
Table 1. Patients with breast cancer diagnosed between 1988 and 2004. Differences in 
numbers are due to missing patient chart entries. a Patients not included in prognostic but in 
the treatment response prediction analysis. n.a., Not available.
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Inclusion criteria for this  retrospective analysis were documented follow-up 
and availability of tissue paraffin blocks with confirmation of breast cancer 
diagnosis. Two patient groups were included: cases with ERα-positive breast 
cancer patients treated with tamoxifen (n = 148) and controls  without 
tamoxifen treatment including ERα-negative and ERα-positive patients (n = 
51). Last inquire date was July 2006 with a median follow-up of 76.8 months 
(6.4 years). Tamoxifen treatment was according to standard guidelines119. 
3.2. DNA and RNA extraction
3.2.1. Isolation from formalin fixed paraffin-embedded tissue blocks
Preparation of tumor cores
In order to isolate nucleic acids from an enriched fraction of breast tumor 
cells, tumor cores from tissue blocks were taken. For that, a specific device 
with a 1.5 mm diameter hollow needle was used and cylinders of 2 to 5 mm 
length were punched out from the block (Figure 12). Selection of the tumor 
area was done under light microscopy screening of an initial hematoxilin-
eosine stained section. The areas of interest were then marked on the block, 
superimposing the section’s outline and marked areas. 
         
      
Fig. 12 Hollow needle punching 
device for tissue core selection. After 
light microscopy inspection of 
hematoxilin-eosin stained sections, 
distinct areas of normal, invasive and 
in situ breast cancer were selected 
us ing co lo r d i sc r im ina t i on . 
Transposition of the identified areas 
back to the block surface allowed 
specific core removal.
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Isolation of nucleic acids 
Standard xylene deparaffinization resulted in low yields of nucleic acids, 
probably due to the thickness of the tissue core. Therefore, a new protocol 
was established. Tissue homogenization from tumor tissue cores was done by 
alkaline heat pretreatment in a buffer containing 10 mM Tris (pH 9), 0.5% 
Tween, 1 mM EDTA, 5% Chelex and 1% ME (for RNA isolation). This 
procedure melts the paraffin and disrupts formaldehyde-protein cross-linking. 
Following overnight digestion with proteinase K (0.5 mg/mL) at 56°C a simple 
boiling step was added to inactivate proteinase K. Following centrifugation 
and rapid cooling on ice the cleared lysate was separated from the solidified 
paraffin. For RNA or DNA isolation an acidic or pH 8 buffered phenol/
chloroform extraction, respectively, of the cleared lysate followed by standard 
0.3 M sodium acetate/2.5 Vol ethanol precipitation completed the isolation. 
When one single tissue core of tumor tissue was available, simultaneous 
RNA/DNA extraction was performed, as follows: the addition of acidic phenol/
chloroform allowed separation of the organic/inorganic phases in order to take 
the upper phase for RNA isolation, leaving the genomic DNA fraction within 
the interphase. For the first, 1 Vol isopropanol and 0.1 Vol 2 M sodium acetate 
(pH 4) was mixed and RNA precipitated at -20°C for 2h or overnight. RNA 
pellet was resuspended in 20 µL of DEPC water and photometer 
measurements were done, confirmed by an agarose gel control. RNase 
inhibitor was added for long-term -20ºC storage. For the DNA genomic 
fraction a pH 12 conversion buffer (10 mM Tris, 1 mM EDTA) was added and 
the recovered aqueous phase precipitated with 0.5 M ammonium acetate/2.5 
Vol ethanol at -20°C for 1h or overnight. Pellet was dissolved in 25 µL TE (10 
mM Tris/0.1 mM EDTA). DNA and RNA yields were assessed by photometry 
and electrophoresed in a 1%TAE gel for quality screening. 
3.2.2. Isolation from breast cancer cell lines
Preparation of cell pellets
Cells  cultured in flasks  were washed in PBS and detached by short 
trypsination. The addition of DMEM+10%FCS medium (see section 3.4.1.) 
stopped  trypsin activity and brought cells into the solution to be taken out. An 
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approximate volume of 10 ml was kept at 4°C for immediate soft 
centrifugation and PBS washing of pellet cells. 
RNA extraction from cell lines
Total RNA Isolation Reagent (TRIR) was used to isolate RNA from cell pellets 
(Thermo Scientific, Hamburg, Germany). To disrupt cells and dissociate 
nucleoprotein complexes the TRIR reagent was added followed by incubation 
5 min on ice. The reconstitution of two phases  through chloroform 
conditioning allowed the separation of the upper aqueous phase followed by 
isopropanol RNA precipitation according to manufacturer’s instruction. 
DNase treatment
Given the absence of an intronic region downstream of promoter A of ESR1, 
appropriate primer design was not possible to prevent amplification from 
genomic contamination templates. Therefore, quantification of transcripts in 
mRNA stability assays of cell lines was preceded by DNase treatment. The 
reaction was performed as shown in Table 2.
Table 2. DNase treatment mix. The 30 µl  volume reaction was incubated at 37°C/30 min; and 
stopped at 85°C/5 min.  
 
DNase treated RNA was purified using 1 Vol phenol-chloroform and 0.2 M 
sodium acetate, pH 4. Following centrifugation for 15 min at 10,000 rpm the 
aqueous phase containing RNA was precipitated with 1 Vol isopropanol. After 
centrifugation for 15 min at 14,000 rpm at 4°C the supernatant was discarded 
and the pellet was washed in ice-cold 70% DEPC-ethanol. The RNA pellet 
was dried and eluted in 15 µl DEPC-water. 
      
DNase mix 30 µl 
DNase buffer (10x) 3 µl
DNase (1 U/µl) 2 µl
Water-DEPC 4.5 µl
RNase inhibitor (40 U/µl) 0.5 µl
RNA (0.5 - 3 µg) 20 µl
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3.3. mRNA expression
3.3.1. cDNA synthesis
Since RNA derived from paraffin-embedded tissues  is highly degraded, 
involving the loss of the poliA-tail, cDNA was synthesized using a mix of 
random-hexamer primers and gene-specific primers  in a proportion of 1:3, 
respectively. The premix was set to 1 µg total RNA and 250 ng random 
hexamer primers (optionally with 10 pmol gene specific primers) and filled up 
to 15 µl with DEPC water. Following a denaturating heating step at 70°C the 
reaction was incubated 2 min at RT to allow random hexamer annealing. M-
MLV reverse transcriptase (Promega, Mannheim, Germany) mix was added 
subsequently as shown in table 3.
    
Table 3. cDNA synthesis reaction mix. After thorough mixing, reactions were incubated at 
37°C/1 h and stopped at 70°C/10 min. The synthesized cDNA was stored at -20°C.
 
3.3.2. RT-PCR
Qualitative RT-PCR reactions were run initially to optimize primer and cDNA 
amount conditions. Amplification with 45 cycles was necessary to detect the 
three main ESR2 isoforms i.e. ESR2_ß1, ESR2_ß2/cx, and ESR2_ß5 as  well 
as ESR1 studied transcripts i.e. ESR1_C and ESR1_exon3. Moreover, the 
addition of total MgCl2 to 2.5 mM per reaction contributed to enhance reaction 
specificity (Table 4). Primers were designed spanning introns for amplicons of 
70-90 bp.
      
Reaction mix 10 µl
5x first strand-buffer (Promega) 5 µl
dNTPs (stock 10 mM/each) 1.25 µl
RNase inhibitor (Invitrogen, 40 U/µl) 0.5 µl
M-MLV (Promega, 200 U/µl) 1 µl
DEPC water 2.3 µl
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Table 4. RT-PCR reaction. Five microliters of cDNA (1:5 dilution) were added for a 45 cycles 
PCR run: 95°C/15min (Taq-activation), 45 cycles each for 93°C/20s, 60°C/30s, 72°C/30s, 72°
C/5min. Products were electrophoresed in a 2% TAE agarose gel at 84 V for 20min.
3.3.3. Real-Time PCR
Real-time PCR with relative quantification was performed by TaqMan® 
assays (Applied Biosystems, Foster City, CA) to measure transcript levels  of 
ESR1 and ESR2 isoforms. Target genes (TG) transcripts  were normalized 
using the housekeeping gene ß-Glucuronidase (GUS) as endogenous 
reference gene (RG). For calibration of tumor expression, tissues from benign 
breast lesions of 7 patients were used. A sample specific mix consisting of 
cDNA and PCR reagent was  prepared with water to a final volume of 20 µl per 
well. Distribution with a multi-channel pipette ensured equal volumes across 
triplicates. Levels of ESR1_C, ESR1_ex3, ESR2_ß2/cx and ESR2_ß5 
transcripts were determined by qPCR mix with respective specific probes. The 
remaining ESR2_ß1, and the GUS transcripts, were assessed by 
SYBRGreen chemistry (ABgene, Hamburg, Germany). In a subsequent step, 
primers alone or with probe were added to a final volume of 25 µl. Reactions 
were run in a 7500 Real Time instrument (ABI) as shown in Table 5.
Table 5. Twenty five microliter Real-time PCR mix. Run: 95°C/15min, 45 cycles each for 95°
C/15s, 60°C/60s.
      
RT-PCR 25 µl 
Hotstar master mix (Qiagen 2x) 12.5 µl
Primer FW (3-5 pmol) 1 µl 
Primer RV (3-5 pmol) 1 µl 
MgCl2 (25 mM) 1 µl 
Water 4.5 µl
Sample specific mix (20 µl) SYBRGreen mix or qPCR mix (2x) ABgene 12.5 µl
cDNA (1:4 dilution) 4 µl
Water 3.5 µl
Primer/probe mix (5 µl) Primers (100 pmol → 3-6 pmol) 0.75-1.5 µl
Probes (100 pmol → 5 pmol) 1.25 µl
Water Up to 5 µl
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The ESR1_exon3 probe was used for the detection of all ESR1 transcripts 
(ESR1_ex3). The ESR1_C probe was designed to specifically bind to the 
5’UTR of promoter C identifying promoter C driven transcripts (ESR1_C). Due 
to the absence of an intronic region downstream of promoter A we restricted 
the analysis of patient samples to ESR1_C and ESR1_ex3 transcripts in order 
to avoid false positive measurements from genomic DNA contamination 
(Figure 13). For ESR2_ß1, ESR2_ß2/cx, and ESR2_ß5 isoforms, reverse 
primers were designed specifically to bind the respective variable sequence at 
exon 8, while the forward one was common to all isoforms placed within exon 
7 (figure 14). All probes were added in 5 pmol concentration. Primers are 
shown in table 6.
Table 6. Primers and probes designed for Real-time PCR. n.p. no probe was used.
34       38   63              67    49   33      4 kb 
ESR1_C ESR1_ex3 
Fig. 13 Annotation for ESR1 transcripts, ESR1_C and ESR1_ex3. Blue vertical  bars 
represent CpG sites; UTR, untranslated region; CDS, coding region.
      
ESR1_C F: CTCGGCCCTTGACTTCTACA
R: GGCAGAAGGCTCAGAAACC
3 pmol   
3 pmol    
FAM probe TGATCCAGCAGGGTAGGCTTG
ESR1_ex3 F: CGGCTCCGTAAATGCTACGA
R: AACATTCTCCCTCCTCTTCGG
3 pmol   
3 pmol
Yakima-
Yellow 
probe
TGGGAATGATGAAAGGTGGGATACGAAA
ESR2_ß1 F: TCCATGCGCCTGGCTAAC
R: CAGATGTTCCATGCCCTTGTT
5 pmol   
5 pmol n.p.
ESR2_ß2 F: CAGGCATGCGAGGGCAGA
R: CATCGTTGCTTCAGGCAAAAGAGT
6 pmol   
6 pmol
FAM Probe CCTCTCAAACACTCACCTCATTTGGAATGAAGAT
ESR2_ß5 F: GGGAAAAGTGTCTGCAAGTTAAGG
R: TCGTTGCTTCAGGCAAAAGAG
5 pmol   
5 pmol
FAM Probe AATGAATGCCTCATTTGGAATGAAGATGGA
GUS F: GCTCATTTGGAATTTTGCCG
R: ATCCCCTTTTTATTCCCCAGC
4 pmol   
4 pmol n.p.
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ESR2_ß1 
!55 kb 
Exon 0K 
ESR2_ßcx 
!55 kb 
ESR2_ß5 
Fig. 14 Annotation for ESR2 transcripts, ESR2_ß1, ESR2_ß2/cx and ESR2_5. Vertical  bars 
represent intronic regions. 
Quantification was achieved by the ∆∆Ct method. Mean Ct values for RG and 
TG were obtained from triplicates. The ∆Ct (test sample) was calculated as: 
Ct (TG) - Ct (RG), and equivalent Ct value were calculated for the calibrator 
samples: ∆Ct (calibrator sample) = Ct (TG) - Ct (RG). Normalized values are 
derived from the formula ∆∆Ct = ∆Ct (test sample) - ∆Ct (calibrator sample) 
and relative expression was  defined as (X-fold) = 2-∆∆Ct. Cutoff values for 
under- (low) and over-expression (high) in breast cancer tissues were defined 
based on standard deviations (STD`s) from the mean Ct value of the 
calibrator samples: strong up/down (>/< 10 STD’s), moderate up/down (± 2-10 
STD’s), no regulation (± 0-2 STD’s). For a bimodal classification, low 
expression was defined as  being within the range of calibrators or absent, and 
high expression was defined as exceeding 2 STD’s of the calibrators mean 
value. 
3.3.4. mRNA stability assay
MCF-7 cells were cultured in triplicate 3,5 cm diameter plates at a density of 
7,5x105 cells/plate in DMEM-10%FCS medium enriched with 10-9 M estradiol 
(see 3.4.1.). For transcriptional inhibition actinomycin D, 1 µg/ml (Biochemica, 
Schwerin, Germany), was added next day and cells were harvested at time 
points 0, 1, 3, 6, 9, 12, 25 hours by addition of cell lysing solution (TEC-kit, 
Nidderau, Germany). The ERα-negative MDA-MB-231 cell line was 
transfected with 170 ng of both pcDNA3.1_ESR1_A and pcDNA3.1_ESR1_C 
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plasmids and cells were treated with actinomycin D and lysed at 4 time points: 
0, 3, 9, and 24 hours after transcription inhibition. Cells  at time zero were 
harvested immediately after actinomycin D addition for reference. Following 
total RNA extraction (see section 3.2.2.) 300 ng to 1 µg of purified DNase 
treated RNA was taken for cDNA synthesis (see section 3.3.1.). Real-time 
PCR was performed in triplicate for each of the cultured triplicates for a total 
of nine replicates per recovered time point. Transcript levels for ESR1_A, 
ESR1_C and ESR1_ex3 were quantified by normalization with 18S-rRNA 
measurements. This choice was related to the fact that 18S-rRNA transcripts 
are less prone to decay over time as protein coding transcripts usually are. 
Because of its high level of expression, cDNA was diluted 1:5,000 for this 
assay. Real-time assays used the same ESR1_C and ESR1_ex3 primers 
described before. To measure ESR1_A and 18S-rRNA transcripts  primers 
were chosen as in Table 7. Calibration of mean expression levels at the six 
time points was done by the comparison to the mean at time zero. 
 Table 7. Real-time PCR primers to complement mRNA stability assay analysis.
 
3.3.5. mRNA expression of target genes upon treatment
The activation of downstream ER target genes after anti-estrogen treatment of 
transfected cell lines were assessed by mRNA measurements. Cells were 
transfected with full-length cDNA constructs (see section 3.5.1.) 
pcDNA3.1_ESR1_A and pcDNA3.1_ESR1_C. For that, two breast cancer cell 
lines were cultured in DMEM+10%FCS medium (see section 3.4.1.): the ERα-
positive and low ERß-positive MCF-7; and the ERα-negative and low ERß-
positive MDA-MB-231. Prior to transfection, cells  were starved in 5% CCS for 
2 days and seeded in a 24-well plate at a density of 105 cells/ml for 24 hours. 
Cells  were transfected at 70% confluence with increasing amounts of the 
      
ESR1_A F: GCTGCGTCGCCTCTAACCT
R: GGCAGAAGGCTCAGAAACC
18S-rRNA F: ACCGCAGCTAGGAATAATGGA
R: GCCTCAGTTCCGAAAACCA
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referred constructs in duplicates: 0 ng, 5 ng, 25 ng, and 125 ng in DMEM
+10%FCS medium. Next day, duplicated wells were either not treated, or 
treated with 4-hydroxy-tamoxifen (4-OH-TAM, 5x10-8 M). After 24 hours, cells 
were harvested with 150 µl total RNA lysis buffer and duplicates were pooled 
together. RNA was isolated and DNase treatment was performed as 
described in 3.2.2. After cDNA synthesis, Real-time PCR was used to 
quantitate the following loci: progesterone receptor (PgR), cyclin D1 (CCND1), 
trefoil factor 1 (pS2), GUS, ESR1_C, ESR1_A, and ESR1_ex3. Primers and 
probes were added at 3 pmol/µl concentration in a total of 15 µl PCR volume. 
Target genes were assessed using Sybr Green with primers shown in table 8. 
PgR F: CGCGCTCTACCCTGCACTC
R: TGAATCCGGCCTCAGGTAGTT
CCND1 F: CCGTCCATGCGGAAGATC
R: ATGGCCAGCGGGAAGAC
pS2 F: TCGACGTCCCTCCAGAAGA
R: GGGACTAATCACCGTGCTG
  Table 8. Primers for Real-time PCR of ER down-stream target genes.
3.3.6. In Silico analysis of ESR1 RNA secondary structure
Secondary structure of the two specific transcripts ESR1_C and ESR1_A 
5’UTRs was generated using mfold software www.frontend.bioinfo.rpi.edu.
RNA secondary structure prediction involved the determination of the most 
stable structure given by its free energy. This energy was calculated by the 
sum of the energy of the structural loops, assuming their independency from 
the rest of the structure125. 
3.3.7. Statistical analysis
Qualitative and quantitative statistical comparisons between transcript levels 
and ERα-status were done by Pearson’s Chi square and Spearman 
correlation. To test for an association with clinical outcome, event-free survival 
(EFS) and overall survival (OS) were analyzed by calculating Kaplan-Meier 
estimations followed by comparisons with Log-rank test. EFS was defined as 
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the time from surgery to the occurrence of either local or distant recurrence, 
contra-lateral breast cancer, or death from any cause. OS was defined as the 
time from surgery to death from any cause. Patients who were alive without a 
breast cancer related event or a second non-breast primary cancer were 
censored at the date of last follow-up. Multivariate Cox regression was used 
to adjust for prognostic clinical factors and a likelihood test was performed to 
test for the independent contribution of molecular factors to the outcome 
variable. All p values were two-sided and values < 0.05 were considered 
statistically significant. All tests were run using SPSS v12.1. To calculate 
mRNA half-lives and exponential decay curves Prism v4.0 was used. Two-
way ANOVA test was applied to compare replicate values.
3.4. Culture of breast cancer cells
3.4.1. Cell culture
Liquid nitrogen frozen aliquots of 3 to 5 million cells  of breast cancer cell lines 
MCF-7, T47D, MDA-MB-134, MDA-MB-157 and MDA-MB-231 were rapidly 
thawed in 37°C pre-warmed water bath. Following a brief centrifugation, cells 
were re-suspended in fresh DMEM enriched with 10% fetal calf serum. The 
cell suspension was seeded in a small flask containing medium and cultured 
in a total volume of 10 ml for 2 to 3 days until 100% confluence. Cells were 
washed in PBS and detached through short trypsination. A fraction of the cell 
suspension was inoculated into a bigger culture flask (17 ml) where it was 
maintained and passaged until a certain experiment was completed. Cultures 
were grown in DMEM with the addition of 10% FCS and enriched with 10-9 M 
estradiol (Gibco-Invitrogen, Karlsruhe, Germany) at 37°C in 5% CO2 
atmosphere. The growth was controlled daily under light microscopy to ensure 
adherence, vitality and pH condition indicated by color switch of the medium. 
Depending on the growth time, cells   were split 2 or 3 times/week to ensure 
optimal growing conditions. Old medium was removed by vacuum suction, 
cells were washed in PBS, trypsinised and passaged to fresh medium. In 
order to seed a certain number of cells  for transfection experiments, a 
Neubauer counting chamber was used which also allows inspection of the 
      
64
cells shape and vitality. To avoid overlapping of cells  on the counting grid, any 
cell suspension was diluted by a factor of five. Hence, the absolute cell 
density is given by: mean count from 4 fields x 10,000 x 5 (cells/ml). 
3.4.2. Transient transfections
MCF-7 ERα-positive and MDA-MB-231 ERα-negative breast cancer cells 
were seeded in triplicates at a density of 5x104 cells in 24-well plates. 
Cells  were transfected with increasing amounts of pcDNA3.1_ESR1_A and 
pcDNA3.1_ESR1_C constructs  (X = 0, 10, 100 and 200 ng). The transfection 
of the empty vector pcDNA3.1 provided baseline expression levels regardless 
of experimental overexpression. Transfections were carried out using 
effectene transfection reagent (Qiagen, Hilden, Germany) according to the 
supplier’s recommendations. Briefly, DNA at a total amount of 200 ng was 
diluted in EC buffer and enriched with enhancer. After stringent vortex the 
solution was  incubated at RT/5 min. The addition of effectene (incubation RT/
10 min) creates a coat of cationic lipids to the condensed DNA molecules 
which provided an efficient way to transfer DNA into eukaryotic cells (Table 9). 
Lastly, transfection complex was diluted with medium and added dropwise 
onto the seeded cells, and incubated for 24-48 hours.
Transfection reagents Per reaction well 
(262 µl)
pcDNA3.1_ESR1_A or pcDNA3.1_ESR1_C or pcDNA3.1 (10-200 ng) DNA1 µl
pUC18 (x ng, to fill up to 200 ng) DNA2 µl
EC buffer 58.4 µl
Enhancer 1.6 µl
Effectene 2.5 µl
DMEM medium 200 µl
Table 9. Transfection reaction. DNA1, plasmid DNA to transfect; DNA2, pUC18 plasmid to 
reach 200 ng DNA input.
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The following day, cells  were washed with PBS and lysed with 150 µl of 1x 
SDS containing lysis  buffer (Promega). Then, 50 µl were used for western blot 
assay (see section 3.8.)
3.5. Cloning 
3.5.1. Generation of full length cDNA ESR1 constructs 
The full-length of ESR1_A and ESR1_C cDNA were amplified using Pfu taq 
polymerase (Stratagene, CB Amsterdam, Netherlands) with EcoRI and XhoI 
tagged oligonucleotides (ESR1_full-A_EcoRI_Fw: GAA TTC GAG CTG GCG 
GAG GGC GTT; ESR1_full-C_ EcoRI_Fw: GAA TTC ACA CAC TGA GCC 
ACT CGC A; ESR1_fullTR_XhoI_Rv: CTC GAG GGG ATT ATC TGA ACC 
GTG TGG). See Table 10.
  Table 10. Amplification of full-length ESR1 isoforms from cDNA.
After PCR check on a 0.8% agarose gel, the products were purified using a 
column based purification kit (Millipore Montage PCR Cleanup) and digested 
with EcoRI and XhoI (NEB) restriction enzymes as shown in Table 11. 
  Table 11. Preparation of cDNA inserts by restriction digest. 
  Digestion at 37°C/2 h and inactivation at 65°C/10 min.
      
cDNA MCF-7 3 µl = 30 ng 
10x buffer 5 µl
dNTPs (10 mM) 1 µl
Primer FW (5 pmol/µl) 1.3 µl
Primer RV (5 pmol/µl) 1.3 µl
Pfu taq polymerase (3 U/µl) 1 µl
H2O 37.3 µl
Purified PCR product 46 µl
EcoRI  (10U/µl) 2 µl
XhoI (10U/µl) 2 µl
Buffer 2xTango 6 µl
H20 4 µl
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Each of the newly purified cDNA sequences were ligated into EcoRI/XhoI 
digested pcDNA3.1 expression vector (Invitrogen, Karlsruhe, Germany) using 
T4 ligase (NEB, Frankfurt am Main, Germany) (Table 12). 
  Table 12. Ligation of the insert to the vector in a 5 µl volume 
  reaction for 1 hour at RT. Reaction was stopped for 5 min at 70°C.
Three microliters were taken to transform E. Coli Top10 competent cells 
(Invitrogen, Hamburg, Germany).  Annotations of the two plasmids are shown 
in Figure 15.
  
Fig. 15 pcDNA3.1_ESR1_A and pcDNA3.1_ESR1_C constructs: the orange sequence refers 
to the specific ESR1_full-length_cDNA, the green sequence refers to the common pcDNA3.1 
hCMV promoter, the green square refers to the specific 5’UTR sequence, the gray lines 
assign the FW_EcoRI and RV_XhoI tagged primers. 
      
ESR1 purified digested plasmids 1 µl = 30 ng
pcDNA3.1 vector, EcoRI/XhoI digested 1 µl = 60 ng
T4 DNA ligase (3 U/µl) 1 µl
10x ligase buffer 0.5 µl
H2O 1.5 µl
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3.5.2. Transformation of Top10 chemically competent E.Coli cells 
An aliquot of 50 µl of competent cells (Top10, Invitrogen) was thawed on ice 
and 3 µl of ligation or 50 ng of plasmid DNA was added to the cells and gently 
tapped. After 20 min incubation on ice, cells  were incubated at 42°C for 
exactly 30 sec and put back on ice. This heat shock procedure forces DNA to 
pass bacterial cell wall of competent cells. Two hundred and fifty microliters 
pre-warmed SOC medium was added and the reaction was shaken at 37°C 
for 1 hour. An aliquot of 100 µl of the grown cells was plated on agar plates 
containing ampicilin (100 µg/ml) for positive colony selection according to 
manufacturer’s  instruction. Plates  were incubated in the oven at 37°C for 
12-14 hours. Next day, grown bacterial clones were picked and inoculated in 
LB medium. To ensure that colonies harbored the correct insert, a PCR from 
selected colonies was performed prior overnight bacterial culture. For that, 
half of each single colony was boiled in 30 µl water and 5 µl of the centrifuged 
supernatant were used for PCR check with a pcDNA3.1 specific primer and a 
ESR1 gene specific primer, chosen to span the insertion site within the 
plasmid. A positive clone was  then grown in LB+Amp medium by shaking 
overnight at 37°C, and plasmids were isolated using a midi-preparation 
plasmid kit (Qiagen100).  
3.6. Electrophoretic Mobility Shift Assay (EMSA)
EMSA was used to study the binding of a putative transcription factor, possibly 
present in nuclear extracts of cells, to the enhancer DNA sequence of 
promoter C of ESR1 (called ERBF-1 or P6 by Tanimoto et al126).    
3.6.1. Preparation of nuclear extracts from cells
A cell suspension of 10-20 million cells was  centrifuged at 750g for 5 min, 
washed in ice-cold PBS and the cell pellet was re-suspended in 1 ml ice-cold 
1x buffer A. In all washing steps the cells  were gently manipulated and kept at 
4°C. After a new centrifugation the cell pellet was  re-suspended in 1 ml ice-
cold buffer A supplemented with 0.4% NP-40 and incubated on ice for 10 min. 
The newly centrifuged pellet was then re-suspended in 200 µl ice-cold 1x 
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buffer B and mixed with a small magnetic stir bar at 4°C during 30 min. This 
procedure promotes the mechanical disruption of the nucleus membrane. The 
nuclear lysate was centrifuged at 7500g for 15 min and the supernatant 
containing the nuclear proteins were taken. The protein content was 
measured by 5x Bradford dye binding and photometry according to supplier’s 
instructions (Biorad). The content per one million cells was between 1-5 µg/µl 
when dissolved in 200 µl buffer B. Nuclear extracts were stored at – 80°C until 
usage. 
3.6.2. Preparation of the fluorescence labeled probe
To prepare the P6 probe two single stranded complementary oligos, 
ESR1_C_ERBF-P6-Fw (5’- GCC CAT GGA ACA TTT CTG GAA AGA CGT 
TCT TGA TCC AGC AGG -3’) and ESR1_C_ERBF-P6-Rv (5’- GCC TGC TGG 
ATC AAG AAC GTC TTT CCA GAA ATG TTC CAT GGG -3’) were mixed 
together, denaturated at 95°C for 10 min and re-annealed to form a dsOligo (5 
µM) by slowly cooling down. The dsOligo harboring one or two guanosine 
base overhangs was labeled in a 20 µl volume reaction using Klenow 
(Fermentas, Frankfurt, Germany) end-repair activity and incorporation of 
Cy5.5 fluorescent dCTP as show in table 13. 
 Table 13. Fluorescent labeling of EMSA oligo probe. The enzymatic reaction took 
 place at 30°C /30 min followed by purification with G50 sephadex according to 
 manufacturer’s instruction (Amersham).
      
dsOligo (5 µM) 2 µl = 10 pmol = 200 ng (30 mer)
Klenow buffer 10x 2 µl
Cy5.5 dCTP (1 mM) 1 µl = 50 µM
Klenow fragment (diluted to 1 U/µl) 1 µl = 1U
H2O 12 µl
d’GAT’TP mix (0.5 mM) 2 µl
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3.6.3. DNA-protein binding reaction
A 5% PAGE non-denaturating gel (10 cm x 10 cm) was prepared for 
electrophoretic mobility shift in 0.5x TBE buffer. The 2x DNA/protein binding 
buffer was optimized from Tanimoto et al126 by substitution of glycerol with 5% 
ficoll to achieve better band resolution. As a competitor for nuclear factor 
binding to the labeled enhancer sequence, non-labeled P6 dsOligo was used 
at 50-fold excess. A nonspecific competitor DNA poly(dIdC) was included in 
the binding reaction to minimize the binding of nonspecific proteins  to the 
labeled target DNA. These repetitive polymers  provide an excess of 
nonspecific sites to adsorb proteins in crude lysates that will bind to any 
general DNA sequence. Specific nuclear extracts, the binding buffer, and all 
competitors  were  incubated  on ice  for 15 min. The  probe  was  then  added
Table 14. DNA-protein binding reaction. Amounts are in µl; N.E. nuclear extracts; c, 
competitor; PC, positive control. 
and the 20 µl reaction again incubated on ice. The DNA-protein binding 
reaction is  shown in Table 14. A labeled Sp1 oligo served as positive control in 
MCF-7 extract known to contain Sp1 transcription factor (last lane).
Binding reactions were loaded along with a sample dye in a separate slot and 
run at 80 v for 1 hour in a 0.5x TBE buffer in a cold room. A fluorescence 
reader (Odyssey system, Li-cor) was used to scan the fluorescing band-shifts 
in gel according to supplier’s instructions.
      
     
Reagents
MDA-
157
MDA-
157 +c
MDA-
134
MDA-
134 +c
MCF-7 MCF-7 
+c
T47D T47D 
+c
MCF-7 
+PC
2x binding
buffer
10 10 10 10 10 10 10 10 10
Poly-dIdc (1 µg/µl) 1 1 1 1 1 1 1 1 1
Competitor (c, 5 µM) 0 2 0 2 0 2 0 2 0
H2O 6 4 6 4 6 4 6 4 6
N.E. (2-4 µg) 2 2 2 2 2 2 2 2 2
Probe (20 ng =1:5) 1 1 1 1 1 1 1 1 1
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3.7. Immunohistochemistry
3.7.1. Tissue microarray (TMA)
In order to study several different breast cancer tissues on a single section, 96 
selected formalin-fixed paraffin-embedded tissue cores were arrayed on a 
microscopy slide. For that purpose, paraffin blocks with sufficient breast tumor 
tissue were selected and punch cores from identified tumor areas were taken. 
The preparation and spatial organization of the tissue cores was done by 
Zytomed (Berlin, Germany) who assembled them in a custom-arranged 
order and prepared microtome sections mounted on slides. The prepared 
sections of the TMA block were used for immunohistochemical analyses. 
3.7.2. Staining for ERα
A tissue section was stained using anti-ERα protein AB (1D5; Dako, 
Carpinteria, CA), according to manufacturer’s  instructions. Bimodal IHC ERα-
status was assessed by Remmele scoring categories, in which 0-2 refers to 
ERα-negative and 3-12 to ERα-positive status127. 
3.7.3. Staining for ERß isoforms
ERß1: mouse anti-human ERß1, Serotec® PPG5/10 
Epitope: C-terminus 512-530aa hERß1 (P7: CSPAEDSKSKEGSQNPQSQ)
A dewaxing step with microclear was followed by re-hydration of the paraffin 
tissue and antigen retrieval in boiling 0.01 M citrate buffer pH 6. After cooling 
down, paraffin sections were washed in TBST and the activity of endogenous 
peroxidase blocked with 0.3% hydrogen peroxide in methanol. Sections were 
then transferred to TBST pH 7.4 buffer and blocked for half an hour with 
normal rabbit serum diluted in TBS containing 5% BSA (NTB). In two separate 
steps, avidin and biotin (vector) were incubated on the tissue. For the 
primary AB reaction, the PPG5/10 (10x, Serotec®) diluted in NTB 1:10 was 
incubated overnight at 4°C in a humidified chamber. The following day, 
sections were thoroughly washed in TBST and incubated with the secondary 
biotinylated horse anti-mouse AB (vector M0405) diluted 1:100 in NTB for 1 
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hour at RT. After thorough washing in TBST, sections were incubated with the 
ABC complex (vector vectastatine elite) previously mixed in PBS buffer for 1 
hour. Avidin has high affinity for biotin (label at the secondary AB) and binds  to 
solution B that contains the oxidase enzyme. The ABC complex has then the 
reporter enzyme to metabolize the DAB-chromogen substract (DAKO) added 
on the sections and incubated 10 min at RT. In the presence of the enzyme, 
DAB produced a brown precipitate that is  insoluble in alcohol. The final 
washing step in running water was followed by Mayers’s hematoxylin 
counterstaining and alcohol dehydration. After mounting and drying the 
section it was ready for light microscopic inspection. 
ERß all isoforms: rabbit anti-ERß, MYEB polyclonal antibody
Epitope: NH2 -terminus 1-12 aa ERß (MDIKNSPSSLNS)
Following the dewaxing step with microclear, paraffin sections were re-
hydrated and submitted to antigen retrieval in boiling 0.01 M citrate buffer pH 
6. After cooling down, sections were washed in TBST and the activity of the 
endogenous peroxidase was blocked with ready-to-use blocking solution 
(Envision DAKO). After thorough washing in TBST tissue sections  were 
incubated with anti-ERß primary AB diluted 1:50 in antibody diluent from 
DAKO. Following another washing step, incubation with the ready to use 
polymer HRP rabbit/mouse  (DAKO) completed the secondary AB reaction. 
Finally, the DAB-chromogen (DAKO) substrate was added for the peroxidase 
enzyme to produce a brown precipitate. Sections were washed and 
counterstained with Mayers’s hematoxylin for 10 sec. After washing in running 
water sections were dehydrated in increasing alcohol concentrations and 
mounted.
ERß2/cx: sheep anti-ERß2/cx polyclonal antibody
Epitope: C-terminus of ERß2/cx (MKMETLLPEATMEQ)
The AB was a courtesy from Dr. Gustafsson (Department of Medical Nutrition 
and Biosciences, Karolinska Institute, Novum, Hudding, Sweden).
Paraffin sections were deparaffinized and rehydrated in decreasing alcohol 
concentrations. For antigen retrieval, sections were boiled in 5% urea and 
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washed in PBS after cooling down. Incubation in 0.3% hydrogen peroxide in 
methanol for 5-10 min blocked endogenous peroxidase activity. A second 
blocking step preventing unspecific binding involved the incubation in 
BlockAce (Serotec® BUF029). After briefly tapping-off the sections, the 
primary AB reaction took place with anti-ERßcx diluted 1:100 in PBS and 
overnight incubation at 4°C. Next day, after thorough washing sections were 
incubated with biotinylated anti-sheep rabbit AB diluted 1:200 in 10% 
BlockAce/PBS at 37°C for 1 hour. Following another stringent washing step, 
sections were incubated in ABC complex (vector vectastatine elite) 
previously mixed in PBS buffer for 1 hour at RT. To develop color, the DAB-
chromogen substract (DAKO) was added to form a brown precipitate. After 
washing, sections were counterstained with Mayer’s hematoxylin for 10 sec 
and washed in running water. Following the dehydration step with increasing 
concentrations of alcohol sections were mounted. 
3.8. Western blotting
For whole cell lysates preparation, cells were lysed by heating at 95°C in a 
SDS containing buffer. Samples were electrophoresed in a 10% SDS-
Polyacrylamide gel and electroblotted onto nitro-cellulose membranes (400 
mA/ 15 min) (Schleicher and Schuell, Dassel, Germany). After blocking with 
5% skim milk powder (Fluka, Steinheim, Germany) membranes were 
incubated for 1 hour with F-10 mouse anti-ERα antibody (1:500; Santa Cruz 
Biotechnology, Heidelberg, Germany) and mouse anti-β-Actin antibody 
(1:5000; Sigma, Munich, Germany) followed by secondary goat anti-mouse 
HRP-conjugated antibody at 1:5000 dilution (Dianova, Hamburg, Germany). 
Detection was performed using SuperSignal WEST DURA/PICO 
chemiluminescent substrate (Pierce, Bonn, Germany) and visualized with a 
chemoluminiscent reader (Las1000, Fuji). 
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3.9. Methylation study 
ESR promoter methylation was studied using two complementary approaches 
i.e. first: qualitatively, using bisulfite restriction analyses (BRA) and 
methylation-specific PCR (MSP), and second: quantitatively, using mass-array 
system (MAS). The qualitative study had the purpose to screen the 
methylation status of promoter A and C of ESR1 as well as of promoter 0N 
and 0K of ESR2, by using a simple and inexpensive method like BRA. 
Promoter C, which contains few CpG sites, mostly concentrated at its 3’-end 
and 5’UTR, was analyzed by restriction with TaiI endonuclease (Fermentas, 
St. Leon-Rot, Germany). Similarly, promoter 0N was analyzed by BstUI 
endonuclease (NEB, Hamburg, Germany). Contrarily, ESR1 promoter A has a 
true CpG island with more than 500 bp and a CG content of 55%, as expected 
from regions close to transcription start sites128. Consequently, MSP was a 
more appropriate methodology to simultaneously screen a higher number of 
CpGs. Promoter 0K at ESR2 was not suited to be assessed by BRA given the 
fact that the three digestion sites for BstUI restriction enzyme did not give a 
clear and unequivocal pattern. Hence, on the qualitative level promoters C of 
ESR1 and 0N of ESR2 were studied by BRA, while promoter A of ESR1 and 
promoter 0K of ESR2 were assessed by MSP. Analyzed regions are depicted 
in Figures 16 and 17.
         Fig 16. Annotation of ESR1 methylation amplicons for qualitative assessment 
         (yellow boxes). Blue vertical bars represent CpG sites. UTR, untranslated region.  
 
      
ESR1_PC
ESR1_PA_90
ESR1_PA_192
ESR1_PA_131
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        Fig 17. Annotation of ESR2 methylation amplicons for qualitative 
        assessment (orange boxes). Vertical blue bars represent CpG islands. 
        UTR, untranslated region. 
3.9.1. Bisulfite treatment
Genomic DNA (0.5-3 µg) was bisulfite treated to convert unmethylated 
cytosines to uracil leaving methylated cytosine residues of CpG sites 
protected from conversion using EZ DNA Methylation Kit (ZYMO RESEARCH, 
Orange CA, USA). Although 500 ng of genomic DNA was  suggested for 
optimal results, PCR fragments were brighter and there were less dropouts 
when 3 µg genomic DNA were used. For that, 130 µl of the CT conversion 
reagent were added to 20 µl of each DNA sample. After careful mixing, 
samples were incubated at 98°C for 10 min followed by 2.5 hours at 64°C. 
Then, 400 µl of M-binding buffer were mixed to samples and the solution 
transferred to a column to be centrifuged 1200g/ 5 min, after which the flow-
through was discarded. A washing step with 400 µl M-washing buffer was 
accomplished after centrifugation at 1200g/ 5 min. Subsequently, 200 µl of a 
M-desulphonation buffer was added to each sample and incubated at RT for 
20 min. After centrifugation, two washing steps with 400 µl of M-washing 
buffer were followed by elution of the bisulfite modified DNA in 30 µl of M-
elution buffer. The treated DNA was stored at -20°C. 
3.9.2. Bisulfite restriction analyses 
The choice for BRA in the context of qualitative CpG-methylation status was 
based on the availability of endonucleases able to recognize converted 
sequences containing CpG dinucleotides for identification of methylated sites. 
From the bisulfite modified DNA, 40 to 240 ng were used for nested PCR of 
ESR1 and ESR2 promoter regions. PCR reactions were carried out using 
HotStar DNA Taq polymerase master mix (QIAGEN, Hilden, Germany) and 
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additional MgCl2 to a total of 3 mM per PCR. The nested design seen in Table 
15 was necessary to obtain clear bright bands. 
Table 15. Primers for bisulfite restriction analysis.
From the 25 µl PCR volume, 5 µl were taken for agarose check in a 1.4% gel 
and the remaining 20 µl were digested with specific endonucleases. For 
diagnostic purposes, a 4% agarose/metaphor (1:1) -TAE gel was used to load 
the complete digestion reaction and run at 85 volts for 30 min. To evaluate the 
methylation status three methylation states were assigned: 0: unmethylated, 
1: partially methylated and 2: fully methylated, according with the restriction 
digestion. 
3.9.3. Methylation specific PCR
For methylation specific PCR, primer pairs  were designed for three loci at 
promoter A of ESR1 and one locus for promoter 0K of ESR2: ESR1_A_192 
(-533 to -341); ESR1_A_131 (-472 to -341); ESR1_A_90 (-212 to -122); 
ESR2_0K (466 bp upstream 0K transcription start site). Primers for a given 
locus were designed to distinguish methylated from unmethylated CpG 
sequences at regions where primers anneal. The selection takes place by 
specific primer annealing at early PCR amplification cycles and is highly 
sensitive. Two PCR reactions were performed for each DNA sample, one 
specific for methylated CpGs for the region of interest, and one specific for 
unmethylated CpGs. The presence of bands at expected size indicates the 
existence of methylated (M) or/and unmethylated (U) alleles in the original 
sample. MSP specific primers included 3 CpG sites each to ensure accurate 
      
Loci BRA Primary PCR Secondary PCR Endonu-
clease
No. 
CpGs 
ESR1_PC F: GAGGGGTTGTTAAGTGTTTTGTT
R: AAATCAAAACAAACCTACCCTACT
F: TTGGTTGTTTTTYGAATTTTTG
R: AACAAACCTACCCTACTAAATCAAA
TaiI  
(ACGT) 2
ESR2_0N F: AAATTTGTAGGG(CT)GAAGAGTAGG
R: ACCGACCTTACCTTCTCTAAAATAC
F: AAGCACGTGTCCGCATTTTAG
R: GTACTTTTCCCRCATTAAAAA
BstUI
(CGCG) 3
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distinction between methylated and unmethylates DNA sequences. MSP 
specific reverse primer was common to ESR1_PA loci and consequently the 
FW primer was the diagnostic one. PCR reactions were carried out using 
HotStar DNA Taq polymerase master mix (QIAGEN, Hilden, Germany). To 
increase yield and specificity a two-step amplification was performed using a 
100-fold dilution from primary low-cycle PCR for a secondary PCR with higher 
number of cycles, as shown in table 16.
   Table 16. Nested PCR reactions for methylation specific PCR.
   U, primers diagnostic of unmethylated sequences; M, primers 
   diagnostic of methylated sequences.
For CpG methylation specific diagnosis, half of the secondary PCR volume 
was loaded on 1.6% agarose TAE gels. PCR products originated from 
methylation specific primer sequences were run side by side with PCR 
products originated from unmethylated primer sequences  at 85 volts  during 20 
min. Methylation status was assigned according to the presence of specific 
bands: 0- unmethylated sample (band from U_PCR and absence of band for 
M_PCR), 1- partially methylated sample (band from U_PCR and band for 
M_PCR), 2- fully methylated sample (band from M_PCR and absence of band 
for U_PCR). MSP primers are shown in Table 17.
      
Primary PCR (25 cycles) 12.5 µl volume
Bisulfite modified DNA 4 µl
Hotstar master mix (2x) 6.25 µl = 1x
U_primer-Fw 0.8 µl = 3.2 pmol
M_primer-Rv 0.8 µl = 3.2 pmol
H2O 0.65 µl
Secondary PCR (40 cycles) 12.5 µl volume
1:100 dilution from primary PCR 2 µl
Hotstar master mix (2x) 6.25 µl = 1x
U_primer-Fw 0.8 µl = 3.2 pmol
M_primer-Rv 0.8 µl = 3.2 pmol
H2O 2.65 µl
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Table 17. Methylation specific PCR primers. Primary PCR of ESR1_PA and ESR1_0K loci 
was run in duplex. M-PCR, methylated specific PCR; U-PCR, unmethylated specific PCR.
3.9.4. Bisulfite sequencing
In order to confirm the accuracy of results  generated by BRA and MSP, 
particularly to control the efficacy of DNA conversion by the sodium bisulfite, 
the PCR products of 12 test samples from paraffin-embedded tissues and 2 
cell lines were sequenced. PCR products were purified using spin-columns 
(Montage, Millipore) and cycle sequenced using either forward or reverse 
primers from PCR assays (Table 18).
Purified modified DNA 2 µl
BigDye Terminator v1.1 premix 2 µl
5x buffer 1 µl
Primer Rv or Fw (5 pmol) 0.6 µl = 3 pmol
HPLC H2O 4.4 µl
            Table 18. Bisulfite sequencing reaction.
Sequencing reactions were performed by using the following thermo-profile: 
96°C/1 min, 25 cycles: 96°C/10 sec, 50-60°C/10 sec, 60°C/2 min. Products 
were purified in shephadex G50 columns by pipetting 750 µl of the slurry 
shephadex into columns, drying the columns by centrifugation at 3000 rpm for 
2.5 min, and loading the sequencing reaction on top of the slurry. Following 
centrifugation the purified eluate was diluted 1:4 and electrophoresed on an 
ABI 310 capillary sequencer (Applied Biosystems).  
      
Locus Primary PCR Secondary M-PCR Secondary U-PCR
ESR1_PA_90 F: AGTTTAGGAGTTGG(CT)GGAGGG
R: GGG(AG)CAAAACAAAAAACTCAAA
F: TTATCGGATTCGTAGGTTTTCG
R: AAAACCAACAAACCACCTAAAAA
F: TGTAGGTTTTTGGGGTAGGG
R: AAAACCAACAAACCACCTAAAAA
ESR1_PA_192 F:GGGGTATATAAGGTAGTATATTAGAGA
R: AAACATCACTCCAAACACAACT
F: CGGTTTTTGGATTCGTTTTTC
R: ACATCACTCCAAACACAACTCAA
F: TGGTTTTTGGATTTGTTTTTTGT
R: ACATCACTCCAAACACAACTCAA
ESR1_PA_131 F:GGGGTATATAAGGTAGTATATTAGAGA
R: AAACATCACTCCAAACACAACT
F: TAGATTTTCGTGCGTTTTCG
R: ACATCACTCCAAACACAACTCAA
F: TGTGTGTTTTTGTTTTTTGGTTG
R:ACATCACTCCAAACACAACTCAA
ESR2_0K F:GYGGTGTAGAAGTGTGAGG
R:CCAAACACTCCAAAACAAAAC
F:GAGTTTGGCGCGTTTTTC
R:CCAAACACTCCAAAACAAAACA
F:GGAATTGGAGAGTTTGGTGTG
R:CCAAACACTCCAAAACAAAACA
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3.9.5. MassARRAY system (EpiTYPER) for quantitative methylation
EpiTYPER (Sequenom®) is  a bisulfite treatment based method for detection 
and mass spectrometric quantification of DNA methylation. Bisulfite treatment 
produces methylation dependent sequence variations of C to T in the 
amplification products. These C/T variations appear as G/A variations in the 
subsequent cleavage products of RNA transcribed PCR products using RNA 
base-specific cleavage. These G/A variations result in a mass difference of 16 
Da per CpG site, which is detected by the MassARRAY-system (Figure 18). In 
the mass spectrum, the relative amount of methylation can be calculated by 
comparing the signal intensity between the mass signals of methylated and 
unmethylated template. 
Fig. 18 Schematic  workflow for quantitative methylation assessment by MassARRAY using 
Matrix Assisted Laser Desorption/Ionization time-of-flight mass spectometry (MALDI-TOF 
MS).
The quantitative study included 190 samples and two loci on a 384-well plate 
format corresponding to the SpectroCHIP® microarray format. DNA 
corresponded to 126 breast tumors, 52 normal mammary tissues from tumor 
blocks, 6 carcinoma in situ from tumor blocks and 6 benign disease breast 
tissues. A positive fully methylated control and a non-template control were 
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included in the analyses. For cost reasons, only  informative samples which 
passed quality checks on 1.8% TAE gels were submitted to the full protocol of 
mass spectrometry. 
PCR design
Given the fact that the qualitative methylation assessment showed positive 
correlations with ESR1 and not with ESR2, quantitative measurements were 
done only at ESR1 promoters. A PCR reaction was  performed with bisulfite 
modified DNA (Table 19) and primers designed using specific software 
recommended by Sequenom (www.urogene.org/methprimer). This  software 
allowed the prediction of CpG islands based on the primary DNA sequence 
and primers are suggested for stretches limited by CpG sites  avoiding areas 
where the primer sequence may contain CpG dinucleotides (Figure 19). 
During PCR amplification of the target region, a T7 promoter for in vitro 
transcription is  introduced to the 5’ end of one strand of each amplicon in 
order to generate a DNA template for transcription into RNA, which is part of 
later mass spectrometric detection steps.         
     Table 19. Amplification PCR for quantitative methylation (MassARRAY 
     system) in a 4.8 µl volume reaction. Cycling profile: 94°C/15 min, 45 -
     50 cycles: 94°C/20 sec, 62°C/30 sec, 72°C/1 min, 72°C/3 min. 
 a
      
Bisulfite treated DNA 1.2 µl
Hotstar master mix (Qiagen) 3 µl
MgCl2 (25 mM) 0.24 µl = 1 mM
Primer mix (T7 RV/10mer FW) 1.2 µl = 0.2 µM (each)
H2O 0.36 µl
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            Fig. 19 Prediction of CpG islands and primer design for promoter A (a) and 
            promoter C (b). F1-5 and R1-5 refer to different primer pair suggestions.
Four loci at promoters A and C were identified which fulfilled basic 
requirements i.e. to encompass amplicons  with less than 200 bp with 
cleavage sequences informative for more than 3 CpG. ESR1_PA5’ locus was 
not analyzable given the fact that CpG sites were too close to give 
measurable independent masses with respect to the correspondent CpG and 
ESR1_PAm showed a poor PCR performance for the whole group of tested 
samples, probably related to the long amplicon size of 162 bp. Primers for the 
selected loci, ESR1_PC3’ and ESR1_PA3’ are depicted in table 20.
Table 20. Primers for MassArray® system. Uppercase are original  primer sequences, reverse 
primer (R) bold sequence corresponds to the T7-promoter incorporated into the amplification 
product for in vitro transcription, forward (F) primer bold sequence corresponds to a 10mer-
tag that balances the PCR primer length.
Preparation of reactions for MassArray system
After completion of PCR, shrimp alkaline phosphatase (SAP) was added to 
each reaction to degrade unincorporated nucleotides (Table 21). 
      
Loci Primers Amplicons
ESR1_PC3’ F aggaagagagTTTTTTTGTTTAGTTTATATATTGAGTTAT
R cagtaatacgactcactatagggagaaggctTCAAAACAAACCTACCCTACTAAATC
147 bp 
(4 CpG)
ESR1_PA3’ F aggaagagagTTTGGGATTGTATTTGTTTT
R cagtaatacgactcactatagggagaaggctCCACCTAAAAAAAAAACACAACC
145 bp
(11CpG)
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     Table 21. SAP for a single reaction. Incubation at 37°C/20 
     min followed by inactivation of SAP at 85°C/5 min.
Next, PCR reactions were split into 2 aliquots and added to T cleavage and C 
cleavage specific RNA-transcription mixes. The mixes contain T7 RNA 
polymerase, rNTPs, reaction specific protected T or C nucleotides and 
RNaseA (Table 22). 
     Table 22. Simultaneous reaction for reverse transcription 
     and T or C specific cleavage. Reactions were incubated 
     at 37°C/3 h.
Prior to mass spectrometry, products were desalted by specific resin 
(Sequenom®). A MassARRAY® Nanodispenser was used to spot a small 
quantity (<100 nL) of reactions onto a SpectroCHIP® microarray. The 
SpectroCHIP® was subjected to matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) using MassARRAY® 
READER mass spectrometer. By the aid of the EpiTyper Analyzer 
(Sequenom®, Hamburg, Germany) a graphical representation of the CpGs, 
the EpiGram, and tables with results and corresponding spectra were 
retrieved.   
      
RNase free Water 3.14 µl
5x T7 Polymerase Buffer 0.89 µl
Cleavage Mix (T or C) 0.24 µl
DTT (100 mM) 0.22 µl
T7 RNA & DNA Polymerase (50 U/µl) 0.44 µl
RNase A 0.06 µl
Total Volume 5.0 µl
RNase free Water 1.70 µl
Shrimp alkaline phosphatase (SAP) 0.30 µl
Total Volume 2.00 µl
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Statistical analysis
Raw values appeared as a proportion of a total of 100% methylation. Based 
on histogram screening of the frequence of methylation within each studied 
CpG site, a score was applied as follows: less or equal to 0.10, 0; 0.10 and 
0.40, 1; greater or equal to 0.40, 2. All correlations used Spearman rho test 
and were run using SPSS v12.1.
3.10. Buffers
3.10.1. Basic buffers
50 x TAE Tris base 242 g
Acetic acid (conc.) 57.1 ml
EDTA (0.5 M) 100 ml
H2O Fill up to 1 L 
Ethydium bromide Stock (10 mg/ml) 500 µl
H2O 20 ml
5x TBE (pH 8.2) Tris-base 54 g
Boric acid 27.5 g
EDTA pH 8 (0.5 M) 20 ml
H2O Fill up to 1 L
Na-EDTA (pH 8) 0,5M Na-EDTA*2H2O 18.6 g
NaOH-Pellets Adjust pH 
H2O Fill up to 100 ml 
Tris-HCl  (pH 7.6) 1M Tris base 12.1 g
HCl (conc.) 6 ml
H2O Fill up to 100 ml
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3.10.2. Buffers and solutions for nucleic acids extraction
TE pH 7.6 (10 ml) Tris 1 M 100 µl = 10 mM
Na-EDTA 0.5 M 20 µl = 1 mM
H2O-DEPC Fill up to 10 ml 
TE pH 9 (10 ml) Tris 1M 100 µl = 10 mM
Na-EDTA 0.5M 20 µl = 1 mM
H2O-DEPC Fill up to 10 ml
6N NaOH Adjust to pH 9 
TEC pH 7.6 (10 ml) Chelex100 100 mg = 5%
TE pH 7.6 1990 µl
TTEC pH 9 (10 ml) Chelex100 100 mg = 5%
Tween20 10 µL = 0.5%
TE pH 9 1980 µl 
TE 10/1 Tris-HCl 1 M (pH 8) 100 µl
Na-EDTA 0.5 M (pH 8) 20 µl
H2O Fill up to 10 ml
TE 10/0.1 Tris-HCl 1 M (pH 8) 100 µl
Na-EDTA 0.5 M (pH 8) 2 µl
H2O Fill up to 10 ml 
3.10.3. Buffers and solutions for Agarose-electrophoresis
1 x TAE (running buffer) 50 x TAE 20 ml
H2O Fill up to 1L
DNA loading dye (6x) Ficoll-400 (15%) 1.5 g
Xylene cyanol (0.25%) 0.025 g
Bromophenol blue (0.25%) 0.025 g
H2O Fill up to 10 ml
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3.10.4. Solutions for the cell culture
DMEM-10%FCS DMEM (4°C) 500 ml
FCS (-20°C) 50 ml
Na-pyruvate (100 mM, 4°C) 5 ml 
Gentamycin (50 mg/ml, 4°C) 0.5 ml
Active coal Norit A 5 g
Dextran (MW > 700,000) 0.5 g
Tris base 0.2428 g
H2O Fill up to 1 L
Adjust pH to 8.0
5%CCS FCS (37°C/30min) 500 ml
Sulfatase (37°C/2h) 2 U/ml
Active coal (pH 8.0) 200 ml 
Incubate 56°C/30min; centrifuge 15min/3000G after cooling on ice. Supernatant CCS is 
sterile filtered and stored -20°C.
3.10.5. Solutions for bacteria transformation
Mg2+ stock (2 M) MgCl2*6H2O 20.33 g
MgSO4*7H2O 24.65 g
H2O Fill up to 100 ml
Filter sterilized
SOC medium (100 ml) Bacto-tryptone 2 g = 2%
Bacto-yeast extract 0.5 g = 0.5%
NaCl2 (1 M) 1 ml
KCl (1 M) 0.25 ml
Mg2+ (2 M) 1 ml = 20 mM
Glucose (2 M, sterilized) 1 ml = 20 mM
NaOH (10 N) Adjust pH 7
H2O Fill up to 100 ml
Add glucose after autoclaving the solution with the remaining ingredients. Pass it through a 
0.2 µm filter.
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Ampicilin Ampicilin 20 mg/ml 200 mg
H2O 10 ml
Store at 4°C in 1 ml aliquots
LB agar plates LB agar 40 g
H2O 1 L
ampicilin 20 µl
Add ampicilin below 55°C temperature.
3.10.6. Buffers for nuclear cell extracts
10x Buffer A (500 µl) HEPES pH 7.9 (1 M) 50 µl = 100 mM
MgCl2 7.5 µl = 15 mM
KCl 50 µl = 100 mM
1x Buffer A 10x Buffer A
DTT (1 M) 1 mM
PMSF (100 mM in ethanol) 0.5 mM
PMSF is added to 1x Buffer A immediately before use
1x Buffer B (1 ml) HEPES pH 7.9 20 µl = 20 mM
NaCl (1 M) 420 µl = 0.42 M
MgCl2 1.5 µl = 1.5 mM
EDTA 0.4 µl = 0.2 mM
Sterile-filtered and stored at 4°C
1x Buffer B before use PMSF (100 mM) 0.5 mM
Aprotinin (10 mg/ml = 1%) 0.1%
DTT (1 M) 1 mM
Sterile-filtered and stored at 4°C
3.10.7. Buffers for EMSA
10x annealing buffer (10 µl) NaCl 500 mM
Tris-Cl pH 7.5 500 mM
MgCl2 100 mM
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d’GAT’TP mix (0.5 mM) d’ATP (100 mM) 1 µl = 25 µM
d’GTP (100 mM) 1 µl = 25 µM
d’TTP (100 mM) 1 µl = 25 µM
H2O 197 µl
5% PAGE (10 ml) Acrylamid/bis (40%) 1.25 ml
TBE 5x 1 ml
Millipore H2O 7.45 ml
To polymerize: TEMED 10 µl
APS (10%) 75 µl
The gel polymerizes in 30 min
Binding buffer (2x) Tris pH 7.5 20 mM
NaCl 100 mM
EDTA 1 mM
MgCl2 2 mM
DTT 4 mM
Ficoll 50 µl = 5%
H2O Fill up until 1 ml
Sample buffer (10x) Glycerol 300 µl
H2O 700 µl
Bromophenol blue (0.05%) 0.5 g
Xylene blue (0.05%) 0.5 mg
3.10.8. Buffers for SDS-PAGE
Running gel (10% 10 ml) ddH2O 4.8 ml
PAA stock (29:1 40%) 2.5 ml
Tris pH 8.8 (1.5 M) 2.5 ml
SDS (10%) 0.1 ml
To polymerize: APS (10%) 0.1 ml
TEMED 10 µl
Overlay the poured gel with isopropanol and wait for polymerization (30 min)
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Stacking gel (5% 4 ml) ddH2O 2.9 ml
PAA stock (29:1 40%) 0.5 ml
Tris pH 6.8 (1 M) 0.5 ml
SDS (10%) 40 µl
To polymerize: APS (10%) 40 µl
TEMED 4 µl
Pour the stacking gel on the running gel after decanting the isopropanol  and wash with 
ddH2O
3.10.9. Buffers for IHC
TBS 10x NaCl 87.66 g
Tris 60.55 g
dH2O Fill up to 1 L
HCl conc. Adjust pH 7.4
TBST pH 7.5 (10x) NaCl 80 g = 1.37 M
KCl 2 g = 27 mM
Tris 30 g
Tween 80 1 ml = 0.1%
H2O Fill up to 1 L
PBS pH 7.4 (10x) NaCl 80 g = 1.37 M
KCl 2 g = 27 mM
Na2HPO4 14.4 g = 101 mM
KH2PO4 2.4 g = 18 mM
H2O Fill up to 1 L
Urea (5%) urea 10 g
PBS 1x 200 ml
Citrate buffer (0.01 M) Anhydrous citric acid 3.84 g
dH2O 1800 ml
NaOH conc. Adjust pH 6.0
dH2O Fill up to 2 L
      
88
NTB (133 ml) TBS 1x 95 ml
BSA 5 ml = 5%
Normal rabbit serum 33.3 ml
H2O2 in methanol (1 L) H2O2 1 ml = 0.3%
Methanol (30%) 30 ml
TBS 1x 70 ml
3.10.10. Solutions to purify sequencing products
Shephadex G50 medium 0.75 g
HPLC H2O 10 ml
Hydrate sephadex at least 1 hour (can be stored at 4°C for 3 weeks)
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Chapter 4. Results
4.1. Tumor specific expression patterns of ER
4.1.1. ERα protein expression
ERα staining identified the protein at the nucleus of epithelial cells. 
Occasional cytoplasmic ERα staining was observed, but there was a 
complete absence of ERα expression in stromal cells  of breast cancer 
samples. As  shown in Table 1, 150/211 (71.4%) of breast cancer cases were 
ERα-positive and 60/211 (28.6%) were ERα-negative. ERα-status  was 
positively correlated with PgR-status (r = 0.63 p = 10-4) and inversely 
correlated with histological grade (r = -0.4 p = 10-4). 
4.1.2. ERα mRNA expression
According to the binary cut-off classification for mRNA transcript levels 
ESR1_ex3, i.e. transcripts driven from all promoters, showed high expression 
levels  in 121/196 (62%) of analyzable breast cancer samples. In contrast,  the 
promoter C specific ESR1_C isoform was overexpressed in 47/196 (24%) 
tumors and had a low or absent expression in 129/196 (66%) of patients 
(Figure 20a). Missing values corresponded to 15 samples not suited for the 
analysis. ESR1_ex3 transcript levels  were strongly correlated with IHC based 
ERα scores (r = 0.73 p = 10-6) (Figure 20b). The ESR1_C transcript was only 
expressed in ERα-positive cases, showing overexpression in 50 of the 139 
ERα-positive tumors (36%) for which Real-time PCR could be performed. 
There was a significant correlation between expression level of the ESR1_C 
transcript and protein scores defined by Remmele (r = 0.31 p = 10-5). There 
was no significant association of ESR1_C transcript expression with tumor 
size, nodal status, tumor stage and histological grade. Both ESR1 transcripts, 
ESR1_ex3 and ESR1_C, were correlated with PgR-status (r = 0.52 p = 10-4 
and r = 0.30 p = 10-4, respectively).
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a
 
b
4.1.3. ERß protein expression
Immunohistochemical staining data of ERß protein were collected for the 
ERß1 isoform and by an antibody not discriminating among the various ERß 
isoforms (ERß-all). ERß2/cx staining was not suitable for analysis, given the 
low level of expression in comparison to high background. ERß5 isoform 
could not be detected by IHC given the fact that the number of amino-acids 
difference to the ERß2/cx was too short to define a specific antibody epitope. 
ERß1 isoform was detected in nucleus and cytoplasm of epithelial cells, as 
well as in stroma of breast cancer tissue. In the latter nuclear staining of 
fibroblasts, fibrocytes and endothelial cells was considered. A representative 
example of a tumor section stained with ERß1 is shown in Figure 21. The 
nucleus of inflammatory cells was not included as an ERß1-positive result. 
ERß staining was performed in a microtissue core array platform of 96 cases, 
thus numbers refer to this total of cases (Figure 22). Missing values refer to 
some tissue cores lost during laboratory handling of the array, or absence of 
tumor tissue at the sectioned inspected area. 
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Fig. 20 Expression levels of 
ESR1  transcripts: a Proportion of 
up- and down-regulated samples 
for ESR1_ex3 and ESR1_C 
measured transcripts; b mRNA 
correlation with ERα-status. X-
fold expression refers to 
expression levels relative to 
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Fig. 21 ERß1 staining of an 
invasive ductal  carcinoma 
from the collection: one can 
see the intense nuclear 
staining accompanied by 
some cytoplasmatic staining.
ERß1 staining in the cytoplasm showed a reciprocal expression pattern to 
nuclear staining, i.e. when in the nucleus  the majority of samples were ERß1-
positive, a similar proportion was ERß1-negative in the cytoplasm. Staining of 
ERß1 in the stroma revealed a great proportion of positive cases (69%), a 
number that was slightly lower for the analysis of ERß-all because of missing 
data. 
ERß1 nuclear IHC 
10 / 11%
59 / 63%
25 / 27%
Missing
Positive
Negative
 
ERß1 cytoplasm IHC
7 / 7%
23 / 24%
64 / 68%
Missing
Positive
Negative
 
ERß1 stroma IHC
2 / 2%
65 / 69%
27 / 29%
Missing
Positive
Negative
 
ERß-all nuclear IHC 
20 / 21%
47 / 50%
27 / 29%
Missing
Positive
Negative
Fig. 22 ERß1 protein expression within the nucleus and cytoplasm of epithelial  cells, and in 
the nucleus of fibroblasts within stroma tissue. ERß-all expression denotes the staining of all 
protein isoforms. 
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In addition, ERß1 nuclear staining was inversely correlated with tumor size (r 
= -0.22 p = 0.04) and it had a positive borderline association with PgR protein 
expression (r = 0.22 p = 0.05). 
4.1.4. ERß mRNA expression
Among the three quantitated ESR2 transcripts, ESR2_ß1 was the more 
frequently up- regulated isoform in comparison with ESR2_ß2/cx and 
ESR2_ß5 (Figure 23). 
     
     
Expression of ESR2_ß1 was inversely correlated with histological grade (r = 
-0.24 p = 0.025) while ESR2_ß5 showed a positive association with this 
parameter (r = 0.36 p = 10-3). In line with this, expression levels  of ESR2_ß1 
isoform were found to be inversely correlated with ESR2_ß5 expression (r = 
-0.36 p = 10-4). ESR2_ß2/cx transcript expression was positively correlated 
with ESR2_ß5 (r = 0.24 p = 7x10-3). There was no significant correlation of 
ESR2_ß2 with tumor size, nodal status, tumor stage or histological grade.  
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Fig. 23 Relative expression of 
ESR2  transcript isoforms: ß1, 
ß2/cx, and ß5.   
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In order to test if ERß isoforms are related to the more important classifiers  for 
hormone-receptor status, ER and PgR, correlation analyses were done. From 
the three ESR2 isoforms, only ESR2_ß5 expression had a significant inverse 
correlation with ERα-status  (r = -0.33 p = 10-4). This isoform was down-
regulated in ERα-positive and low grade tumors (r = 0.3 p = 1x10-4) (Figure 
24). Moreover, ESR2_ß5 was inversely associated with PgR-status (r = -0.24 
p = 7x10-3). No further association with tumor size, nodal status, or tumor 
stage was found. There was neither significant correlation between 
expression levels of the three studied ESR2 isoforms and nuclear protein 
expression of ERß1 (Figure 25), nor with cytoplasmic and stroma protein 
staining (data not shown). There was also lack of correlation between mRNA 
transcript levels  and protein expression data for ERß-all staining. ERß1 
nuclear staining was positively correlated with the cytoplasmic ERß1 protein 
determination (r = 0.37 p = 10-3). 
   
4.2. ER expression and survival
For survival analyses of all patients, sub-groups were defined with low (down-
regulation) and high (up-regulation) ESR1_exon3 and ESR1_C transcript 
levels. In univariate analysis neither standard bimodal IHC derived ER-status 
(Figure 26a) nor ESR1_exon3 mRNA expression were associated with OS 
(Figure 26b). In contrast,  low  levels  of  ESR1_C  transcript were significantly 
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Fig. 24 Correlation of 
ESR2  mRNA isoforms with 
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associated with a more favorable OS when compared to high levels (Figure 
26c, p = 0.017). These results are derived from all patients  irrespective of 
hormone receptor status. The ERα prognostic value shown in figure 26a for 
the studied breast cancer cohort demonstrates the limited value of the ERα 
protein detection to discriminate between favorable and unfavorable breast 
cancer outcome. In fact, between 5 and 8 years follow-up the group of ERα-
positive patients start to have a decreased survival in comparison with the 
ERα-negative group. The herein reported data represent a subset patient 
collection (n = 211) of a large breast cancer database with more than 20 years 
of follow-up, where the same trend was observed (Log-rank p < 10-4) (Figure 
27; data kindly provided by Fritz, P. and “Onkologischer Schwerpunkt 
Stuttgart”, OSP).
In relation to ERß expression and survival, nuclear staining of  ERß1  was 
significantly correlated with tamoxifen adjuvant treatment response (r = 0.24 p 
= 0.029). On the other hand, ERß1 expression in the cytoplasm was positively 
correlated with recurrence and death (r = 0.22 p = 0.04). Corroborating this 
tendency, ERß1 expression at the cytoplasm of epithelial cells showed a trend 
for decreased EFS (Log-rank p = 0.06). Of note, ESR2_ß5 transcript showed 
a borderline inverse association with OS (r = -0.21 p = 0.049). 
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a     b
  
c
Fig. 26 Kaplan Meier overall survival curves for all patients calculated from a follow-up period 
of 16 years: a stratified according to ERα-status; b stratified according to ESR1_ex3 
transcript levels; and c stratified according to ESR1_C transcript levels.
 
Fig. 27 Overall survival of almost 15,000 breast cancer patients stratified by ERα-status and 
PgR-status with a follow-up period of 18 years: the present work includes 211 patients (Figure 
26a), corresponding to a subset of this database (http://www.egms.de/en/meetings/
gmds2008/08gmds136.shtml). 
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4.3. ER expression and prediction of tamoxifen response
The relevance of ESR1_C transcript levels  for the prediction of treatment 
response of adjuvant tamoxifen treated patients was investigated. Cases with 
less than 3 months follow-up or ERα-negative tumors were excluded. Low 
levels  of the ESR1_C transcript were associated with lower recurrence and 
death rates when compared to patients  with high expression levels  (Figure 
28a, p = 0.0013). Multivariate Cox regression including tumor size, nodal 
status and histological grade showed that high ESR1_C expression is an 
independent predictive factor for decreased OS (HR = 2.48; 95% CI, 
1.24-4.99; p = 10-3). To address the discriminatory value of ESR1_C transcript 
expression in patients more likely to benefit from endocrine treatment, i.e 
ERα-positive and progesterone receptor (PgR)-positive tumors, subgroup 
analyses were performed. Low levels  of ESR1_C transcript were associated 
with lower recurrence and death rates within the ERα/PgR double-positive 
phenotype (Figure 28b, p = 3x10-4). Multivariate Cox regression including 
tumor size, nodal status and histological grade showed that high ESR1_C 
expression is an independent predictive factor for decreased OS among the 
double-positive phenotype population (HR = 3.41; 95% CI, 1.45-8.04; p = 
0.005).
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Fig. 28 Overall  survival according with ESR1_C levels of expression: a in tamoxifen treated 
patients and b in the sub-group of ERα/PgR double positive phenotype. 
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4.4. Characterization of methylation status at ESR1 and ESR2 
promoters
4.4.1. Qualitative assessment
Methylation at ESR1 and ERα protein status
CpG methylation at three studied loci of promoter A was positively correlated 
with each other (ESR1_PA_90 vs ESR1_PA_131, r = 0.31 p = 2x10-3; 
ESR1_PA_90 vs ESR1_PA_192, r = 0.23 p = 2x10-2; ESR1_PA_131 vs 
ESR1_PA_192, r = 0.42 p = 10-4). Examples  for MSP analysis are depicted in 
Figure 29. No significant correlation with ERα-status was found (Figure 30). In 
contrast, promoter C (ESR1_PC) methylation was inversely correlated with 
ERα-status (r = -0.28 p = 4x10-4) (Figure 30). This observation most likely 
results from an increased number of fully methylated samples in ERα-
negative and of unmethylated samples in ERα-positive tumors. There was no 
significant association of CpG methylation at promoters A and C with clinical 
parameters such as tumor size, nodal status, histological grade or tumor 
stage. Examples of ESR1_PC restriction patterns as displayed in Figure 31.
     L – M   U   M  U   M   U   M   U   M   U   M  U   M   U   M   U
Fig. 29 Example of Methylation Specific PCR TAE gel for ESR1_90 locus. Products 
generated by methylated (M) and unmethylated (U) PCR were loaded side by side for 
each given sample.
Methylation and ESR1 transcripts levels
There was no correlation between CpG methylation at any of the investigated 
promoter A loci and expression levels  of ESR1_ex3 or ESR1_C transcripts. 
Interestingly, methylation at promoter C was inversely associated with 
ESR1_ex3 expression levels (r = -0.28 p = 5x10-3) representing the total 
population of ESR1 isoforms (Figure 32). 
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Fig. 30 Correlation between CpG methylation status (qualitative approach) at ESR1 
promoters A and C, and ERα-status as a function of incidences among ERα-negative and 
ERα-positive breast tumors. Methyl, methylation; ER-status, ERα-status.
      L - 1, 0,  0, 1,  1, 0, 2, na, 0, na, 1, 0, 1,  2, 0, 0,  0, 0 - L
Fig. 31 Examples of bisulfite restriction analysis for TaiI diagnosis in a 4% TAE gel for 
ESR1_PC: 0 – unmethylated; 1 – partially methylated; 2 – fully methylated; na – non-
applicable. Size was controlled with a 100 bp ladder (L). 
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Fig. 32 Correlation of CpG methylation status (qualitative approach) at ESR1 promoters A 
and C, and levels of ESR1_ex3  and ESR1_C relative expression (Y-axis). Meth, methylation; 
interm, intermediate. Of note, ESR1_C was only expressed in intermediate or unmethylated 
samples at ESR1_PC, which correspond to tumors expressing the ERα protein.
Methylation at ESR2 and ERß protein status
There was no correlation between methylation at either ESR2 promoters and 
ERß1 or ERß-all protein detection (data not shown). In Figure 33 there are 
some examples for ESR2_ON restriction patterns.
Methylation at ESR2 and transcripts levels
A weak inverse correlation between methylation at ESR2_0K and ESR2_ß1 
mRNA expression was observed (r = -0.21 p = 0.033) (Figure 34). No further 
significant associations between methylation at ESR2 and mRNA isoforms 
were detected.
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Fig. 33 Examples of bisulfite restriction analysis for BstUI diagnosis in a 4% TAE gel for 
ESR2_0N: 0 – unmethylated; 1 – partially methylated; 2 – fully methylated; na – non-
applicable. Size was controlled with a 100 bp ladder (L). 
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Fig. 34 Correlation between CpG methylation at promoters 0K and 0N of ESR2 and levels of 
ESR2 transcripts. Meth, methylation; interm, intermediate. 
 
4.4.2. Quantitative assessment
Quantitative methylation at ESR1
As a refinement of the findings from qualitative approaches, CpG methylation 
of ESR1 promoters A and C were quantified using mass spectrometry. One 
locus per promoter was selected based on methodologic limitations, intrinsic 
characteristics  of the DNA sequence, and cost-effectiveness of the procedure. 
Data from methylation at ESR1_PA3 and ESR1_PC3 loci were retrieved from 
11 out of 16 CpGs and 4 out of 4 CpGs, respectively. There was a highly 
significant correlation of methylation status among all CpG sites within 
promoter C (table 23). This pattern was not found for promoter A CpG sites. 
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     Table 23. Spearman’s Rho coefficient correlation matrix among CpG sites at 
     promoter C; p value significant for alpha < 0.05.
For ESR1_PC3, CpG1 site showed the highest level of methylation, while for 
ESR1_PA3, CpG6 was the site with strongest degree of methylation. (Figure 
35). As an internal control, quantitative data were significantly associated with 
previous qualitative assessment (p = 10-5) for selected CpG sites. Figure 36 
shows quantitative methylation spectra.
 
Fig. 35 Histograms for mean quantified methylation at single CpG sites of the studied 
amplicons at promoters C and A of ESR1. Quantification is given in relation to a total of 100% 
methylation within a tumor. 
No significant correlation was observed between the quantified methylation at 
any of the studied loci and patient’s survival (EFS, OS), clinical parameters 
(tumor size, nodal status, tumor stage, histological grade), or outcome from 
treatment with tamoxifen (adjuvant or palliative). 
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a
      b
Fig. 36 Representation of quantitative methylation results for ESR1 loci at promoter A and 
promoter C: for each locus a top scale corresponds to the size of the amplicons, and the 
numbers below to the assigned CpG sites. Each circle represents the methylation status of a 
CpG site in relation to the desaturation of colors from 0 to 100%. a Pre-test run: ESR1_PA5 
amplicon gave results for 2 CpGs in 6, a bad performance dependent on the specific 
sequence; ESR1_Pam amplicon had a good test result but the number of dropouts was too 
high when PCR results were checked; ESR1_PC3 provided data for the 4 CpGs after the 
reading at the individual spectra; b Representative results for the ESR1_PA3 amplicon. pc, 
positive control.
ESR1 quantitative methylation and ERα-status
There was a significant inverse correlation between quantified methylation at 
ESR1_PC3 CpGs and ERα-status (r = -0.23 p = 0.01). The same association 
tendency was seen with PgR-status and methylation at ESR1_PC3 (r = -0.2 p 
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= 0.04). On the other hand, none of the 11 CpG sites at ESR1_PA3 were 
associated with ERα expression (r = 0.08 p = 0.44). 
ESR1 quantitative methylation and transcripts expression
There was no significant correlation between levels of methylation at 
promoter A (ESR1_PA3) and ESR1_ex3 mRNA expression levels. 
Interestingly, methylation levels at ESR1_PC3 were inversely correlated with 
both ESR1_ex3 and ESR1_C transcript levels of expression (r = -0.33 p = 
10-3 and r = -0.36 p = 10-4, respectively) (Figure 37).   
ESR1_ex3
highlow
Su
m 
of 
qu
an
tifi
e d
 m
e t
hy
lat
i on
 sc
o r
es
10
8
6
4
2
0
ESR1 loci
PC3 (4 CpG)
PA3 (11 CpG)
  ESR1_C
highlow
Su
m 
of 
qu
an
tifi
ed
 m
e t
h y
l at
ion
 s c
or
es
10
8
6
4
2
0
ESR1 loci
PC3 (4 CpG)
PA3 (11 CpG)
Fig. 37 Correlation between quantified CpG methylation at ESR1_PA3 and ESR1_PC3 loci 
and expression levels of ESR1 transcripts. The sum of quantitated levels at each separate 
CpG was used as a methylation score and plotted against mRNA expression classes, low and 
high. 
ESR1 quantitative methylation in tumor and normal mammary tissue
Fifty two normal breast tissue specimens were included in the analysis. 
However, many samples  (20 to 30% depending on the locus) did not have 
good readable data. Hence, cases in which there were paired tumor-normal 
comparisons were restricted to 18 for ESR1_PC3 locus and 12 for 
ESR1_PA3. A positive correlation between levels of methylation in tumor and 
paired normal breast samples was found for ESR1_PC3 (r = 0.67 p = 2x10-3) 
(Figure 38), but not for ESR1_PA3 (r = 0.11 p = 0.72). 
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4.5. Mechanistic investigations
4.5.1. ESR1_C and ESR1_A transcript stability in relation to the whole 
ESR1 mRNA (ESR1_ex3)
To investigate a possible molecular mechanism underlying the distinct 
prognostic value of the studied transcripts, mRNA stability was evaluated as a 
potential influencing factor on the regulation of ERα protein expression. First, 
half-life of isoforms ESR1_C and ESR1_A were studied in ERα-positive 
MCF-7 cells. The mean (of nine-replicates) normalized mRNA decay at seven 
time points  after actinomycin D mediated transcription inhibition is shown in 
Figure 39. ESR1_C showed a longer mRNA half-life (t1/2) compared with the 
total mRNA pool obtained from all promoters (ESR1_ex3) that was even more 
pronounced when compared with promoter A driven mRNA (t1/2 ESR1_C = 
7.42 vs  t1/2 ESR1_A = 2.85 hours). This difference demonstrates increased 
2.6-fold higher stability of promoter C transcript compared to promoter A 
transcripts (ANOVA p < 10-3). Interestingly, ESR1_ex3 (t1/2 = 5.12 hours) 
approximately averaged the decay rates of C and A transcripts.
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Fig. 38 Quantified CpG methylation at 
promoter C of ESR1 shows a positive 
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Fig. 39 mRNA half-life for ESR1 transcripts in MCF-7 cells: UTRC, ESR1_C; UTRA, ESR1_A; 
EXON3, ESR1_ex3. mRNA decay was measured at 0, 1, 3, 6, 9, 12, and 24 hours after 
actinomycin D treatment for a total of nine replicates by Real-time quantification.
In a second approach, the ERα-negative MDA-MB-231 cell line was 
transfected with full-length cDNA ESR1_C and ESR1_A constructs, and half-
lives were measured. As these cells have no native expression of ESR1 gene 
only mRNA generated by the correspondent transfection was measured and, 
consequently, ESR1_ex3 decay actually reflects the decay of the respective 
transcript (Figure 40). This experiment intends to evaluate the role of ERα 
expressing breast cancer cell lines in the regulation of promoter C  driven 
transcript, namely through the known ERBF-1 enhancer domain. When using 
the MDA-MB-231 ERα-negative cell line, which lacks  the ERBF-1 enhancer 
domain and potential trans-acting factors, there is no significant difference in 
the half-life of the transcripts. 
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Fig. 40 mRNA half-life for ESR1 transcripts in MDA-MB-231 cells: UTRC, ESR1_C (0.88 h); 
UTRA, ESR1_A (0.95 h); EX3-A, ESR1_ex3  at cells transfected with pcDNA3.1_ESR1_A 
(1.24 h); EX3-C, ESR1_ex3 at cells transfected with pcDNA3.1_ESR1_C (0.83 h). Decay was 
measured at 0, 2, 4, 8, and 12 hours after actinomycin D treatment. 
4.5.2. Investigation of the ERα protein translated from ESR1_C and 
ESR1_A transcripts
Transfection of the ERα-positive (MCF-7) and ERα-negative (MDA-MB-231) 
cell lines with increasing amounts of the respective pcDNA3.1_ESR1_C and 
pcDNA3.1_ESR1_A constructs revealed a proportional amount of blotted 
protein at the same molecular weight of the 66 kDa ERα wild-type protein 
(Figure 41).   
  
  
  MCF-7
  MDA-MB-231
     200,  100,  10,  0,   200, 100, 10,  0    
              ESR1_C                  ESR1_A
Fig. 41 Western-blot detection of ERα protein after 0, 10, 100, and 200 ng of transfected 
pcDNA3.1_ESR1_C and pcDNA3.1_ESR1_A constructs in MCF-7 and MDA-MB-231 cell 
lines. 
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To study the effect of transcriptional inhibition on translated protein, 
actinomycin D treatment experiments  were performed. As shown in Figure 42, 
protein amounts were comparable among triplicates and the protein decay 
associated with transcriptional blocking was similar for both ESR1_C and 
ESR1_A transcripts.  
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Fig. 42 a Western-blot detection of ERα 
protein at 4 time points (0, 3, 9, 24 hours) 
after actinomycin D treatment of MDA-
MB-231 transfected cells with the full length 
c D N A p c D N A 3 . 1 _ E S R 1 _ C a n d 
pcDNA3.1_ESR1_A. The housekeeping 
protein was monitored for normalizing total 
protein content. b Densitometry of the blotted 
bands showing no difference on ERα protein 
amounts between isoforms transfections. 
108
4.5.3. Comparison of ESR1_C and ESR1_A transcript secondary 
structure influencing translation efficiency
In silico analyses of mRNA primary structure showed that 5’UTR_C with 116 
nucleotides is  shorter while having a lower GC content (51.7%) compared to 
5’UTR_A with 163 nucleotides  and a higher GC content (71.8%). The 
predicted RNA secondary structures for the corresponding 5’UTRs have an 
estimated free energy of -72.9 Kcal/mol for ESR1_A (Figure 43b) and -16.2 
Kcal/mol for ESR1_C (Figure 43a). Hence, the ESR1_C transcript has a more 
relaxed structure with AT-rich sequences potentially facilitating translation 
initiation from the 5’UTR of transcript ESR1_C.  
a      b 
Fig. 43 Predicted mRNA secondary structure for a ESR1_C and b ESR1_A. Estimated free 
energy was -16.2 Kcal/mol and -72.9 K cal/mol, respectively. Note the distinct difference in 
structure due to higher proportion of stable G-C stem loops in isoform A.
4.5.4. Investigation of ESR1 promoter C regulation by transcription 
factor-promoter interactions  
To address protein-DNA interactions as a mechanism for promoter C 
regulation driving ESR1_C transcript expression, Electrophoretic Mobility Shift 
Assay (EMSA) experiments were performed using the P6 sequence for the 
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cis-acting enhancer element ERBF-1 at the 5‘UTR_C (See section 3.6.). 
Specific band shifts  were observed for nuclear extracts from 3 of 4 cell lines 
which disappeared when unlabeled competitor  probe was included. Specific 
protein-DNA complexes were seen only within ERα-positive cell lines but not 
in the ERα-negative MDA-MB-231 (Figure 44). Hence, it can be concluded 
that in ERα-positive cell lines a specific trans-acting factor exists that binds 
the ERBF-1 sequence suggesting a potential role of transcription factors 
driving promoter C expression.
 
 
Nuclear 
extract
+ + + +
PC
Competitor + + + +
Fig. 44 Electrophoretic  mobility shift assay using nuclear extracts from MDA-MB-231, MDA-
MB-134, MCF-7, and T47D cell  lines.  PC, positive control (SP1 consensus sequence); ER-, 
estrogen receptor alpha negative; ER+, estrogen receptor alpha positive. Arrows assign 
specific bands and concomitant absence when competitor was included for DNA- protein 
binding complexes at the 5’UTR_C sequence P6 of ERBF-1 (Estrogen Receptor Binding 
Factor-1 enhancer domain).  
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4.5.5. Study of differential activation of downstream target genes 
between ESR1_C and ESR1_A transcripts 
In order to study the expression of selected downstream target genes of ERα 
after 4-OH-tamoxifen treatment of ERα-positive (MCF-7) and ERα-negative 
(MDA-MB-231) transfected cells, mRNA levels of PgR, pS2, and CCND1 were 
measured. Cells were transfected with increasing amounts of full-length 
cDNA pcDNA3.1_ESR1_C and pcDNA3.1_ESR1_A constructs and 
differential target gene expression was measured along with expression of 
ESR1_C, ESR1_A and ESR1_ex3. As expected, ESR1_C levels of 
expression were high in cells transfected with the pcDNA3.1_ESR1_C 
plasmid, with a higher increase in the ERα-positive MCF-7 cell line. Treatment 
with 4-OH-tamoxifen resulted in an increase on ESR1_C, above the 
respective levels without treatment. The magnitude of expression was 
proportional to the amount of the transfect plasmid (not shown) (Figure 45). 
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Fig. 45 ESR1_C expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected with 
125 ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-transfected, 
and having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 125 ng of 
transfected plasmid are displayed.
As shown in figure 46, ESR1_A expression levels were high in cells 
transfected with the pcDNA3.1_ESR1_A plasmid, more in MCF-7 cells  than 
MDA-MB-231; however remnants of expression were detected in MCF-7 cells 
non-transfected with this plasmid, obviously associated with native 
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expression. Treatment with 4-OH-tamoxifen resulted in a significant increase 
of the ESR1_A transcript within MCF-7 cells, but not in the ERα-negative one. 
Levels  of expression were proportional to the amount of the transfect plasmid 
(not shown), but the overall magnitude was higher compared to ESR1_C 
transfection effects. 
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Fig. 46 ESR1_A expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected with 
125 ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-transfected, 
and having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 125 ng of 
transfected plasmid are displayed.
As expected, expression of ESR1_ex3 was higher in MCF-7 than in MDA-
MB-231 cells (Figure 47). There was no significant difference between 
pcDNA3.1_ESR1_A and pcDNA3.1_ESR1_C transfected cells, suggesting a 
similar contribution to the ESR1_ex3 transcript. Treatment with 4-OH-
tamoxifen increased the transcript expression proportionally to the amounts of 
transfected plasmid (not shown). 
Expression of downstream target genes
There was no pS2 expression measurable in MDA-MB-231 cells, irrespective 
from the type of transfected plasmid or mode of treatment (Figure 48). Levels 
of pS2 expression following different pcDNA3.1_ESR1_A and 
pcDNA3.1_ESR1_C transfections was similar in MCF-7 cells. Treatment with 
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4-OH-tamoxifen reduced pS2 expression, with no observed differences 
among overexpressed isoforms. 
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Fig. 47 ESR1_ex3 expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected 
with 125 ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-
transfected, and having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 
125 ng of transfected plasmid are displayed.
!"#$
%%&'"!$
(")$
'%*(")$
%"%$
+*+("#$
'"!$
+)("!$
)"%$
)++)"*$
'"#$
()#"*$
!"#$#$%& !'($#$%& !"#$#$)*& !'($#$)*& !"#$%& !'($%& !"#$)*& !'($)*& !"#$'$%& !'($'$%& !"#$'$)*& !'($'$)*&
!
+
,
-
&.
/
01
,
23
4+
5
&6
+
-
+
&7
8
,
-
93
:3
;,
93
/
-
&
!"#$+<=0+>>3/-&&
Fig. 48 pS2 expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected with 125 
ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-transfected, and 
having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 125 ng of 
transfected plasmid are displayed.
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PgR expression was only present within MCF-7 cells, with monotonous levels 
independent from the type and amount (here not shown) of transfected 
plasmid (Figure 49). Treatment with 4-OH-tamoxifen reduced PgR expression 
to less than 50%. 
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Fig. 49 PgR expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected with 125 
ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-transfected, and 
having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 125 ng of 
transfected plasmid are displayed.
CCND1 expression was detected in both cell lines, but with a significant 
higher level in the ERα-positive MCF-7 one, accounting to 1.25- to 1.8-fold in 
pcDNA3.1_ESR1_A and 1.5- to 2.2-fold in pcDNA3.1_ESR1_C transfected 
cells (Figure 50). The augment on expression in MCF-7 is superior to levels  of 
non-transfected cells, which was not verified for MDA-MB-231. Treatment with 
4-OH-tamoxifen lowered CCND1 expression to a similar level for 
pcDNA3.1_ESR1_A transfected cells while pcDNA3.1_ESR1_C transfected 
MCF-7 cells responded with a less pronounced decrease.
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Fig. 50 CCND1 expression in MCF-7 (MCF) and MDA-MB-231 (MDA) cells transfected with 
125 ng of the full-length cDNA ESR1_A (A) and ESR1_C (C) constructs; or non-transfected, 
and having received 4-OH-tamoxifen treatment (OH) or not (E). Only results for 125 ng of 
transfected plasmid are displayed.
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Chapter 5. Discussion
This  work aims to add new perspectives on factors potentially influencing the 
prognostic value of ER-status in breast cancer. Clinical practice and basic 
research are both built on steroid hormone receptor, particularly the ER, as a 
key regulatory factor for estrogen dependent breast cancer onset, 
progression, therapeutic management, and deregulated estrogen signaling in 
breast cancer. This study focuses on the contribution of mRNA isoforms to ER 
expression as well as on the influence of epigenetic regulation of ESR genes 
to ER-status. The main motivation was driven by clinical uncertainties 
addressing the insufficiently resolved identification of ERα-positive breast 
cancers that don’t respond to tamoxifen treatment.   
ESR1 mRNA isoforms provide a novel classifier for breast cancer 
outcome 
Using the current clinical standard IHC based ERα protein expression as a 
reference, the assessment of ESR1 mRNA provides first evidence for the 
promoter C driven isoform being a potential diagnostic classifier for the 
discrimination of tamoxifen responders from non-responders. It is currently 
recognized that the IHC derived ERα-status does not accurately predict 
patients’ responsiveness to tamoxifen treatment and that its prognostic value 
is  limited118. Interestingly, ERα is not among the listed “Risk Categories” 
defined by the international expert consensus on the primary therapy of early 
breast cancer119. In agreement with this, the present data confirm ERα protein 
as a weak classifier for disease outcome once more underscoring the 
biological and clinical heterogeneity of ERα-positive tumors129,118. Importantly, 
Bentzon et al130 in a comprehensive study of 26,944 patients recently 
provided strong evidence for the ERα prognostic effect being limited to the 
first 5 years after diagnosis. This same observation holds for a large german 
database from which the current breast cancer cohort originates. These 
comprehensive data sets indicate that loss  of immunohistochemically 
assigned ER alone cannot be the sole factor to determine breast cancer 
prognosis. 
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Of note, current array based breast cancer gene signatures for the 
improvement of prognosis and prediction include ESR1 mRNA expression, 
however no information has  been given on specific isoforms131,132. At the 
ESR1 transcriptional level, measurement of total mRNA expression 
(ESR1_exon3) in the present study mirrors  the weak prognostic value of 
protein expression. However, when patients’ outcome was stratified according 
to expression levels of the isoform C, tumors with low expression of promoter 
C driven transcript had a more favorable OS. This  association showed to be 
of particular relevance to the sub-group of ERα-positive patients  treated with 
tamoxifen. At 5 years, patients with high expressing ESR1_C tumors 
experienced significantly shorter survival probabilities. This effect was 
strongest in ERα/PgR double-positive tumors with high levels  of ESR1_C 
isoform suggesting a loss of endocrine responsiveness. Of note, the time 
frame in which the ESR1_C isoform expression showed it’s maximal 
discriminatory power overlaps with the time span of 6 to 15 years  post-
diagnosis  in which the majority of relapses usually occur104. From these 
findings it can be inferred that ESR1_C transcript expression may aid in the 
identification of ERα-positive tumors not responsive to tamoxifen, thus 
extending other tamoxifen resistance principles such as growth factor/ER 
crosstalk109 and metabolic resistance106. It will be of interest to study whether 
ESR1_C transcript levels may help to identify endocrine sensitivity for both 
tamoxifen and aromatase inhibitor treated patients. 
Because ESR1 isoform C is translated into the common 66 kDa wild-type 
ERα protein, other possible mechanisms must explain the observed clinical 
association with mRNA expression levels. ESR1_C and ESR1_A transcripts 
were investigated quantitatively and qualitatively by determining transcripts’ 
half-lives and putative structural implications, respectively. The half-life of the 
ESR1_C isoform in MCF-7 breast cancer cell line was increased by 2.6-fold 
when compared with that of ESR1_A, potentially leading to a greater 
availability as a template for translation. The half-life of the total ESR1 mRNA 
pool (ESR1_exon3) as with previous reports, was estimated to be 5.1 
hours133, averaging the half-lives of isoforms A and C suggesting that they are 
major contributors to ESR1 transcription in breast tumors. Regarding mRNA 
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stability, 3’UTRs are known to be responsible for mRNA degradation through 
deadenylation of the polyA-tail or endoribonucleolytic cleavage in a tail-
independent process134. Yet, ESR1_A and ESR1_C transcripts share identical 
3‘ends and therefore the difference in RNA stability must rather be explained 
by differences at 5’UTRs. Ross135 pointed to the role of 5’UTRs which can 
dramatically affect mRNA half-life through influence on translation efficiency or 
presence of translation-inhibiting stem-loop structural characteristics. Based 
on its 5’UTRs the ESR1 gene may be considered a class I gene (poorly 
translated under normal conditions) that can enhance translation by 
alternative splicing allowing a cell to abandon inhibitory secondary 
structure136. This mechanism may apply to the ESR1_C transcript given its 
relaxed low energy structure in contrast to the tightly base-paired structure of 
the ESR1_A. It has been suggested that the differentially spliced 5’UTR exons 
might regulate ERα synthesis either by influencing turnover or competence of 
translation of ERα mRNA isoforms137. This  alternative splicing mechanism 
could be a critical event for deregulating the tight control of ERα expression in 
breast epithelial cells. 
The clinical investigations  in this  study showed that patients with breast 
tumors expressing high levels of ESR1_C transcript had worse prognosis and, 
furthermore, had a poor outcome with tamoxifen treatment. In line with the in 
vitro experiments it can be suggested that a selective growth advantage may 
be acquired once promoter C is activated, which is particularly evident for 
ERα/PgR double-positive tumors not responsive to tamoxifen. The hypothesis 
of promoter C selective usage by breast cancer cells or a sub-population is 
supported by in vitro findings of a trans-acting factor (ERBF-1) exclusively 
expressed in cells  with promoter C driven ESR1 mRNA expression (formerly 
promoter B). ERBF-1 binds to a transcriptional enhancer element selectively 
used by breast cancer as  a tumor-specific promoter C enhancer126. 
Electrophoretic mobility shift experiments in this study clearly demonstrated 
the presence of a nuclear factor that binds to the aforementioned enhancer 
sequence in ER-positive breast cancer cell lines but not in an ER-negative cell 
line. Strikingly, the DNA-protein interaction was most distinctively seen in 
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T47D, a cell line which among others, showed the highest level of ESR1_C 
expression. 
In summary, ESR1_C and ESR1_A transcripts give rise to the same ERα 
protein which is  expected due to the common acceptor splice site124 and 
hence, at the protein level, the promoter selectivity is indistinguishable. 
However, from our new findings it can be inferred that the limited predictive 
value of ERα-status may be improved by from ESR1 mRNA assessments. 
Based on the functional data, it can be hypothesized that the molecular switch 
leading to promoter C activation by yet uncharacterized trans-acting factors 
does not lead to an increase of overall ER expression levels, but rather may 
destabilize protein turn over. It will be of utmost importance to identify the 
transcription factors acting on promoter C for understanding their potential 
role for acquiring a selective growth advantage through disruption of ER 
signaling and activation of alternative pathways  for cell cycle stimulation. Yet, 
ESR1_C expression measurements  may provide an immediate advantage for 
the assessment of breast cancer prognosis and treatment outcome prediction. 
ER target gene expression and ESR1 isoforms
To evaluate the possibility of distinct downstream gene activation in 4-OH-
tamoxifen treated cells transfected with the two different isoforms, expression 
levels  of pS2, PgR and CCND1 were assessed. Overall, there was no 
significant difference on downstream effects originated from 4-OH-tamoxifen 
treated cells transfected with either ESR1_C or ESR1_A specific constructs. 
Treatment with 4-OH-tamoxifen paradoxically induced ESR1 mRNA levels in 
MCF-7 cells and, as expected, decreased expression of all three studied 
target genes. ER expression was previously reported to become down-
regulated in response to estradiol with subsequent destabilization on mRNA 
levels, while 4-OH-tamoxifen exerted the opposite effect by increasing ER 
expression138. As pS2 gene transcription in MCF-7 cells is  directly induced by 
estrogen139, decreased expression in MCF-7 cells  upon 4-OH-tamoxifen 
treatment is expected from its competitive ER inhibitory action. Moreover, ER 
signaling is connected to cell cycle machinery through co-activators as 
AIB1140. The addition of 4-OH-tamoxifen was reported to abolish the effect of 
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estrogen/AIB1 dependent cyclin D1 expression by a reduction of mRNA141, 
which is confirmed by the present data. ERα and ERß proteins are degraded 
in response to estradiol via the proteasome pathway and tamoxifen stabilizes 
both receptors142. Moreover, the proteasome pathway in MCF-7 cells  is linked 
to transcription activation through ERE binding of ER to regulated promoters90. 
The observation that no differential effects  of the two isoforms on target genes 
activation after 4-OH-tamoxifen treatment exposure might be related to the 
mediated effect through a common ERα protein. Furthermore, it doesn’t take 
into account the role of protein turnover in different biological states i.e. the 
balance between rate of synthesis and rate of degradation143. Alternative 
approaches incorporating protein turnover pathways  thus may provide better 
estimates for the biological significance of the two ESR1 isoforms.  
ERß expression and prognostic value
Presently, only the IHC ERα-status assessment guides tamoxifen treatment 
decisions, specifically through scoring of nuclear stained epithelium. Since 
ERß is a regulatory partner of ERα action, ERß protein and ESR2 isoform 
expression patterns were investigated. Contrary to ERα, mRNA isoforms of 
the ESR2 gene give rise to different proteins  which differ at the carboxy-
terminus, hence the expression of ERß1 isoform as well as ERß-all which 
provides information about all C-terminal truncated ERß proteins were 
analyzed. ERß1 protein, similar to ERß-all staining, was mainly present in the 
nucleus of epithelial and stroma breast cancer cells, a pattern which 
corroborates previous reports71,67. Furthermore, the presence of ERß1 
isoform at the nucleus of epithelial breast cancer cells was significantly 
associated with tamoxifen response. This is  in line with the pure antagonistic 
effect of SERMs bound to ERß at promoters  due to lack of the AF-1 activity in 
ERß144,43. Additionally, ERß has a weaker transcriptional activity at EREs of 
target genes in comparison to ERα, a characteristic that reduces  ERα activity 
whenever heterodimers are formed71,145. Hence, wild-type ERß1 may act in 
consonance by intensifying the anti-estrogenic action of tamoxifen. In 
contrast, ERß1 protein expression in the cytoplasm of epithelial breast cancer 
cells was associated with increased recurrence and death. One explanation 
      
120
for the observed relationship between spatial ERß expression and breast 
cancer outcome could be that cytoplasmic monomeric ERα- or ERß-
expression interferes with the MAPK pathway146, promoting a ligand 
independent activation of ER and downstream target genes. This is supported 
by the presence of phosphorylation sites at the N-terminal AF-1 domain of 
ERß by MAPK potentiating the recruitment of the p160 coactivator SRC-1145. 
In fact, ERß-anti-estrogen complex can activate transcription via non-genomic 
ER signaling pathway that involves the activation of cytoplasmic signal 
transduction cascades such as the Src/ERK and the PI3K/AKT pathway147,148. 
The unequivocal determination of the different ERß protein isoforms is 
hampered by inconsistent IHC methods123,80, differences on primary 
antibodies specificities149, and intrinsic limitations related to the small C-
terminal amino-acid difference between the isoforms. On the other hand, 
differing reports on the influential role of ERß protein isoforms in relation to 
total-protein ERß detection by the common N-terminal epitope recognition 
make results difficult to interpret. The association of ERß expression with 
clinical parameters such as tumor size, nodal status, histological grade and 
stage varies among studies. In this study ERß1 nuclear epithelial staining was 
more frequently associated with smaller tumors. Others  have suggested an 
association of ERß nuclear expression with negative axilar nodal status150, 
low-grade tumors150, better DFS151, and better survival after tamoxifen 
treatment152. Hence, to better understand the value of ERß  for  breast cancer, 
improved IHC ERß detection149 as well as validation in significant number of 
patients are needed. At the biological level, incorporation of spatial ERß 
staining patterns in the cytoplasm of epithelial cells and nucleus of stromal 
cells may add in the comprehension of ERß mechanisms particularly for 
epithelial-stroma interactions in breast tumors. In this context three studies 
were recently published including a large number of patients, validated 
antibodies and accurate statistical approaches148,153,154,155. The work by 
Novelli et al148 showed that high ERß1  expression in the nucleus of epithelial 
breast cancer cells is associated with aggressive phenotypes i.e. HER-2-
positive and triple negative tumors (ERα-, PgR-, and HER-2-negative), and 
stressed the predictive role of this isoform for favorable response to endocrine 
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therapy among patients  with lymph node negative tumors. Honma et al154 
reported that ERß1 expression was a predictive factor for recurrence, DFS 
and OS and underscored the survival advantage for patients with ERα-
negative/ERß1-positive tumors. The latter suggests  modulatory effects on 
endocrine response by ERß1 isoform. These results are in line with findings 
from the present study since the investigated patient cohort had a proportion 
of 54% node negative tumors which may reflect the reported association by 
Novelli et al. Although Honma et al did not look specifically to expression in 
the cytoplasm of epithelial cells, the present data corroborate the importance 
of ERß1 as a putative classifier for survival prognosis. Finally, Shaaban et 
al153 reported on the prognostic role of isoform ERß2 on survival in relation to 
nuclear versus cytoplasmatic location. Due to technical reasons, no data on 
ERß2 protein expression could be obtained in this study, however the aspect 
of spatial allocation of stained isoforms goes in line with the finding observed 
for ERß1 in the present study. 
ESR2 mRNA expression analysis  showed that ESR2_ß1 transcript is over-
expressed when ESR2_ß2/cx and ESR2_ß5 are down-regulated and vice-
versa. ESR2_ß1 expression was higher for low-grade tumors as already 
reported by others68. Moreover, expression of ESR2_ß5 in tumors that have 
lost ERα protein confirm data by others156, which led to suggest an ESR2_ß5 
role in tumor progression. This  is  keeping with our results  pointing for a role of 
ESR2_ß5 over-expression in PgR-negative breast tumors as well as in 
patients with decreased OS. Because levels of ESR2 isoforms could not 
unambiguously be assessed in normal mammary tissue, its  direct role in 
tumor progression remains elusive. Unlike the study by Leygue et al68, higher 
expression levels were found for the ESR2_ß1 isoform compared to 
ESR2_ß2/cx and ESR2_ß5 isoforms. The discrepancy may be due to lower 
sample size of the previous study, or because of different house-keeping 
genes used as  standards to normalize relative expression levels in Real-time 
PCR (GUS turned out the best suited and most stably expressed control for 
gene expression analyses in the present study). As already noted by 
others157, there was no significant correlation between ESR2 mRNA 
transcripts and ERß protein levels. This finding stresses once more the 
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limitations of existent ERß antibodies. Given the intrinsic constraints related to 
small epitope differences between isoforms, the assessment of mRNA 
expression seems indispensable for a comprehensive evaluation of ERß 
expression status158.    
In summary, by incorporating data from mRNA and protein expression, the 
current study strongly suggests a differential role of the currently 
acknowledged ERß isoforms in breast cancer outcome. ERß1 protein isoform 
turned out to better predict the prognosis and response to tamoxifen, while 
mRNA isoforms ESR2_ß2/cx and ESR2_ß5 may represent markers of 
unfavorable tumor phenotypes and/or worse prognosis implying their potential 
role as dominant negative forms of the wild-type ß1. Noteworthy, the 
described influences on breast cancer outcome - predominantly exerted by 
spatial differences between nuclear and cytoplasmatic expression of ERß1 - 
might help ERß to “emerge from the shadows” as recently stated by Speirs155.
Promoter methylation is associated with ER expression
Enzymatic methylation of cytosine residues within CpG nucleotides at gene 
regulatory regions leads to epigenetic gene silencing, e.g. by recruitment of 
histone deacetylases86. Current knowledge about ESR1 epigenetic regulation 
is  mostly based on analyses of CpG islands downstream of promoter A 
including the first exon. These studies  have used Southern blot88 approaches, 
methylation specific PCR159,160, methylight161 and bisulfite genomic 
sequencing162 with a particular emphasizes on promoter A and exon 1 
methylation for ERα loss in human breast cancer tissue and cell lines. In 
contrast, the present work showed that CpG methylation at promoter C and 
not at promoter A is associated with ESR1 silencing. The concomitantly 
observed down-regulation of ESR1 total mRNA expression (ESR1_ex3), in 
promoter C methylated tumors, points to a general influence of promoter C 
methylation in ERα regulation. In line with this notion, hypermethylation at 
promoter A and exon 1 of ESR1 did not correlate with loss of ERα in 
endometrial cancer163 or in breast cancer164. Hori et al164 concluded from their 
observed correlation with a loss of PgR that expression of ERα target genes 
rather than the ERα itself may reflect methylation status at the ESR1 
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promoter. On the other hand, Yoshida et al88 reported that methylation of 
promoter C was important for ERα loss in human breast cancer and, in 
combination with promoter A methylation, was modulating ERα expression. 
Their study implicated Southern blot detection in combination with methylation 
sensitive restriction enzymes and sodium bisulfite genomic sequencing, the 
latter representing the most sensitive and specific approach. In the present 
work, methylation at promoter A was initially examined by means of 
methylation specific PCR. This technique is  considered sensitive with the 
advantage of simultaneously detecting methylated and unmethylated bisulfite 
modified DNA, thereby accounting for DNA integrity165. Given the few CpG 
sites present at promoter C, methylation specific PCR was not possible and 
bisulfite restriction analysis  provided a first qualitative approach. However, a 
relative high number of intermediate methylated samples raised suspicion that 
contamination with normal tissue or incomplete enzymatic digestion due to 
insufficient DNA bisulfite conversion could have been responsible for 
artifactual data retrieval. For that reason, confirmatory data based on 
quantitative methylation assessments were collected. Quantitative ESR1 CpG 
methylation analysis using MALDI-TOF MS has confirmed qualitative findings. 
Although the MALDI-TOF MS platform was originally developed for the 
detection of SNP107 variants the MassARRAY system for quantitative 
detection of epigenetic modifications proofed to be a highly specific and 
reproducible methodology166. Moreover, since promoter C contains few CpG 
sites it was the superior method of choice because other quantitative 
methylation methods, e.g. Methylight167, quantitative-MSP (Q-MSP)168, and 
combined BRA (COBRA)169 either require more dense CpGs or the presence 
of specific cleavage sites, respectively. The data obtained herein for the first 
time implicates promoter C rather than promoter A methylation for ERα loss 
and down-regulation of ESR1 mRNA. It cannot be ruled out that methylation 
downstream promoter A, i.e. at exon 1, affects  transcriptional activity of the 
gene, as was suggested by others. However, the discontinuous methylation 
pattern at regulatory regions of ESR1 is  contradicting the hypothesis  that 
sweep-like dissemination originating from a methylation hotspot has caused 
this  epigenetic pattern170. Rather, the presence of upstream methylated 
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regions at promoter C and putatively downstream located methylation at exon 
1, interspersed by an unmethylated region favors the idea that both promoter 
regions control independent epigenetic mechanisms. It will be highly 
interesting to know how epigenetic modification observed at promoter C 
affects silencing of the total population of mRNA isoforms, given the fact that 
promoter C transcripts are present only in a fraction of ERα-positive breast 
tumors.
No association for ESR2 0N and 0K promoter methylation and gene/protein 
expression of ERß was found in this study. Zhao et al67 have studied promoter 
0N and 0K methylation by bisulfite genomic sequencing in 17 breast cancer 
cell lines, a few normal samples and 33 breast tumors. They reported a 
significant correlation between promoter 0N hypermethylation and loss of ERß 
mRNA expression in both cell lines and tumor samples. In a different 
approach Skliris et al171 suggested methylation dependent ERß protein 
regulation following in vitro experiments  of restoring ERß expression in ERß-
negative cell lines with DNA methyl transferase inhibitors. This  lack of 
concordance may be related to the small sample size as  well as with the 
assessment of methylation status in cell lines, prone to acquire phenotypic 
changes as the number of divisions increase. However, further analyses 
including the use of fully quantitative methods like mass spectometry are 
essential for comprehensive evaluations at both ESR2 promoters. 
In conclusion, the findings of the present study open new insights towards a 
refined understanding of the molecular mechanisms inherent to ER 
expression. Concurrently, the clinical significance was  demonstrated and may 
stimulate further efforts towards clinical applications, e.g. by incorporating 
promoter C specific expression as  a marker for diagnosis and management of 
breast cancer. Investigating the biology of steroid hormone-receptor status 
and its  dysregulation in breast cancer are highly demanded. On the level of 
ER loss the identification of causative epigenetic or microRNA induced 
silencing as well as changes of critical transcription factors  harbor the 
potential for new drug targets aimed to reverse endocrine insensitivity for one 
third of breast cancers. On the other hand, the paradigm of ‘good receptor 
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levels  maximizes endorine therapy’ is challenged in future not only by this 
study. The clinical relevance of ER dysregulation as demonstrated by 
promoter C activation in a significant proportion of breast cancer patients  puts 
the identification of the causative regulatory switch to center stage of intrinsic 
or aquired endocrine resistance. Finally, as evidenced by the exploitation of 
large survival data, the biological meaning of PgR mediated signal 
transduction and spatial expression characteristics of ERß may become 
indispensable towards understanding of hormone receptor action in breast 
cancer.
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